


CHEST Physician®

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS



Lung biopsy micrograph shows perivascular lymphocytic infiltrate, a sign of rejection.

Lung transplantation in the era of COVID-19: New issues, paradigms

BY CHRISTINE KILGORE

MDedge News

Data are sparse thus far, but there is concern in lung transplant medicine about the long-term risk of chronic lung allograft dysfunction (CLAD) and a potentially shortened longevity of transplanted lungs in recipients who become ill with COVID-19.

“My fear is that we’re potentially sitting on this iceberg worth of people who, come 6 months or a year from [the acute phase of] their COVID illness, will in fact have earlier and progressive, chronic rejection,” said Cameron R. Wolfe, MBBS, MPH, associate professor of medicine in transplant infectious

disease at Duke University, Durham, N.C.

Lower respiratory viral infections have long been concerning for lung transplant recipients given their propensity to cause scarring, a decline in lung function, and a heightened risk of allograft rejection. Time will tell whether lung transplant recipients who survive COVID-19 follow a similar path, or one that is worse, he said.

Short-term data

Outcomes beyond hospitalization and acute illness for lung transplant recipients affected by COVID-19 have been reported in the literature by only a few lung transplant programs. These reports – as well as anecdotal experiences being

LUNG TRANSPLANTATION // continued on page 4

COVID-19 pill's effectiveness appears to be less than hoped

BY BRENDA GOODMAN, MA

Merck's newly FDA-approved antiviral pill for COVID-19, molnupiravir, appears to be far less effective than early results from the clinical trial first suggested.

According to an analysis by scientists at the Food and Drug Administration, the experimental pill cut the risk of hospitalization or death from COVID-19 by about 30%, compared with a placebo, and the pill showed no benefit for people with antibodies against COVID-19 from prior infection.

The FDA's Antimicrobial Drugs Advisory Committee narrowly voted to authorize the drug, voting 13-10 to support emergency use, which requires a medication to meet a lower standard of evidence than does full approval.

Molnupiravir (brand name Lagevrio), however, was not destined to be the first FDA-authorized antiviral agent designed as a pill to treat COVID-19. The day prior to molnupiravir's Dec. 23 approval, the FDA granted emergency use authorization of Pfizer's ritonavir plus nirmatrelvir, (brand name Paxlovid), for patients age 12 and up who weigh at least 88 pounds.

COVID-19 PILL // continued on page 7

INSIDE HIGHLIGHT



NEWS FROM CHEST
Meet our new Editor in Chief and board members.

Page 3



IN PARTNERSHIP WITH THE ITALIAN DELEGATION

CHEST®
Congress
2022

Bologna
ITALY | 3-5 February

congress.chestnet.org

POSTAGE AND
FEE PAID
PERMIT NO. 500
HARRISBURG, PA

CHANGE SERVICE REQUESTED

CHEST PHYSICIAN
10255 W Higgins Road,
Suite 280
Rosemont, IL 60018

The people's paper

BY DAVID SCHULMAN, MD, MPH, FCCP

With this issue, we usher in a new era for *CHEST Physician*, as I hand over the reins of Editor in Chief to Angel Coz, MD, FCCP.

I have had the pleasure of serving in this role over the last 4 years, and though I will still have the privilege of appearing within these pages with some frequency as I move into my new role as CHEST President, I would like to mark this milestone by passing along a few thoughts on how *CHEST Physician* has developed over the last few years. Let's reflect on the goals I set for us way back in the January 2018 issue (on page 46 of that issue, for those of you holding onto our back issues).

I've always viewed *CHEST Physician* as "the People's Paper" of CHEST. We don't feature first-run scientific manuscripts and authors aren't likely to reference our articles in other publications. But, your editorial board and our partners at Frontline aim to give our readers a broad overview of recent publications and presentations in pulmonary, critical care, and sleep medicine. This is often accompanied by expert commentary about how those developments might affect the care we provide to our patients.

I can't thank our editorial board members enough for the hours they spend selecting a small number of items to feature among all of the new medical developments each month.

One of the main goals we had established over the last few years was to create more opportunities for *CHEST Physician* to serve as the voice of the members and leaders of



Dr. David Schulman

the American College of Chest Physicians. We achieved the latter part of this goal, with leadership penning quarterly columns on actions of the Board of Regents, developments within the annual meeting, as well as ongoing columns from our Networks.

And, we have also provided a more reliable voice for our members, with authors of our Sleep Strategies, Critical Care Commentary, and Pulmonary Perspectives columns providing a broader and more representative sample of our membership than ever before.

One of the areas where I would love to see more progress is with reader engagement. It has been a delight to receive feedback from CHEST members, even when the author is taking issue with something we have published. *CHEST Physician* will be a better publication than it already is with your ongoing input.

Please, if you see something that we write that you particularly like (or don't!) or if there's something you'd like to see that we haven't written, please reach out to us! You can always reach us at chestphysiciannews@chestnet.org.

In closing, I want to thank all of the steadfast *CHEST Physician* readers for making my 4 years as Editor in Chief enjoyable and meaningful. While I am so pleased with the current state of this publication, I cannot wait to see its ongoing evolution under the leadership of Dr. Coz and his editorial board. ■

NEWS FROM CHEST // 18

SLEEP STRATEGIES // 23

CHEST PHYSICIAN IS ONLINE

CHEST Physician is available at chestphysician.org.



Angel Coz, MD, FCCP, is Editor in Chief of *CHEST Physician*.

CHEST Physician®

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

AMERICAN COLLEGE OF CHEST PHYSICIANS (CHEST)

EDITOR IN CHIEF

Angel Coz, MD, FCCP

PRESIDENT

David Schulman, MD, MPH, FCCP

EXECUTIVE VICE PRESIDENT & CEO

Robert Musacchio, PhD

PUBLISHER, CHEST

Nicki Augustyn, CAE

MANAGER, EDITORIAL RESOURCES

Pamela L. Goorsky

SECTION EDITORS

Aaron B. Holley, MD, FCCP

Pulmonary Perspectives®

Daniel R. Ouellette, MD, FCCP

Critical Care Commentary

Michelle Cao, DO, FCCP

Sleep Strategies

EDITORIAL ADVISORY BOARD

Humayun Anjum, MD, FCCP

A. Christine Argento, MD, FCCP

Abbie Begnaud, MD, FCCP

David L. Bowton, MD, FCCP

Mary Cataletto, MD, FCCP

Carolyn D'Ambrosio, MD, FCCP

Mary Jo S. Farmer, MD, PhD, FCCP

Sachin Gupta, MD, FCCP

Loren Harris, MD, FCCP

Jonathan Ludmir, MD

Diego Maselli, MD, FCCP

Mangala Narasimhan, DO, FCCP

Brandon M. Seay, MD

Shyam Subramanian, MD, FCCP

Sai Venkateshlah, MD, FCCP

CHEST PHYSICIAN, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to CHEST members. Content for **CHEST PHYSICIAN** is provided by Frontline Medical Communications Inc. Content for News From Chest is provided by the American College of Chest Physicians.

The statements and opinions expressed in **CHEST PHYSICIAN** do not necessarily reflect those of the American College of Chest Physicians, or of its officers, regents, members, and employees, or those of the Publisher. The American College of Chest Physicians, its officers, regents, members, and employees, and Frontline Medical Communications Inc. do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to products, drugs, or services mentioned herein.

POSTMASTER: Send change of address (with old mailing label) to CHEST PHYSICIAN, Subscription Services, 10255 W Higgins Road, Suite 280, Rosemont, IL 60018-9914.

RECIPIENT: To change your address, contact Subscription Services at 1-800-430-5450. For paid subscriptions, single issue purchases, and missing issue claims, call Customer Service at 1-833-836-2705 or e-mail custsvc.chph@fulcoinc.com

CHEST PHYSICIAN (ISSN 1558-6200) is published monthly for the American College of Chest Physicians by Frontline Medical Communications Inc., 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609. Subscription price is \$244.00 per year. Phone 973-206-3434, fax 973-206-9378.

EDITORIAL OFFICES 2275 Research Blvd, Suite 400, Rockville, MD 20850, 973-206-3434, fax 240-221-2548

ADVERTISING OFFICES 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609, 973-206-3434, fax 973-206-9378

E-mail: chestphysiciannews@chestnet.org
©Copyright 2022, by the American College of Chest Physicians



FRONTLINE MEDICAL COMMUNICATIONS SOCIETY PARTNERS

EXECUTIVE EDITOR Kathy Scarbeck, MA

EDITOR Mark S. Lesney, PhD

CREATIVE DIRECTOR Louise A. Koenig

DIRECTOR, PRODUCTION/MANUFACTURING

Rebecca Slobodnik

DIRECTOR, BUSINESS DEVELOPMENT

Monique Michowski,

973-206-8015, cell 732-278-4549,

mmichowski@mdedge.com

RECRUITMENT SALES REPRESENTATIVE

Linda Wilson 973-290-8243,

lwilson@mdedge.com

SENIOR DIRECTOR OF RECRUITMENT SALES

Tim LaPella, 484-921-5001,

tlapella@mdedge.com

FRONTLINE MEDICAL COMMUNICATIONS

Corporate

VP, SALES Mike Guire

VP, MEMBER MARKETING & DIGITAL

PRODUCTION Amy Pfeiffer

PRESIDENT, CUSTOM SOLUTIONS JoAnn Wahl

CIRCULATION DIRECTOR Jared Sonners

DIRECTOR, CUSTOM PROGRAMS Patrick

Finnegan

VICE PRESIDENT, PROPRIETARY CONFERENCES, MEDSCAPE LIVE David J. Small, MBA



Meet the new *CHEST Physician* Editor in Chief

Angel Coz Yataco, MD, FCCP, is a Pulmonary and Critical Care specialist at the Respiratory Institute at the Cleveland Clinic. He previously served as the Medical Director of the Intensive Care Unit at the Lexington Veterans Affairs Medical Center and was an Associate Professor of Medicine at the University of Kentucky. Dr. Coz received his medical degree from Universidad Peruana Cayetano Heredia in Lima, Peru. He completed residency training in internal medicine and did his fellowship

training in pulmonary and critical care medicine at Henry Ford Hospital.

Dr. Coz was a member of the 2021 Surviving Sepsis Campaign Guidelines panel and serves on the American Board of Internal Medicine Governance – Critical Care Medicine examination board. He holds multiple leadership positions at CHEST—Chair of the Council of NetWorks; a member of the Guidelines Oversight Committee; and served as the Critical Care Section Editor for *CHEST Physician* since 2018. He has been awarded the Distinguished

CHEST Educator (DCE) designation every year since its inception in 2018 and received the CHEST Presidential Citation Award in 2021.

Dr. Coz has given multiple talks on critical care, sepsis, and pulmonary topics at the national and international level. He has published several peer-reviewed articles and serves as ad hoc reviewer for *CHEST*, *Journal of Critical Care*, *Critical Care Medicine*, *Critical Connections*, *Intensive Care Medicine*, and *Annals of Pharmacotherapy*, among others. ■



Dr. Angel Coz

COURTESY: CHEST

Welcome our new board members and section heads

Humayun Anjum, MD, FCCP – Board Member

Dr. Anjum is currently working as a pulmonary and critical care physician at Baylor Scott & White Medical Center-Grapevine in Dallas, Texas. He is an Adjunct Clinical Assistant Professor at University of Houston and University of North Texas. He recently moved to Dallas from Corpus Christi, TX, where he served as the core faculty for the Internal Medicine residency program and the Pulmonary Disease fellowship program.

He is passionate about learning and teaching and has been very intricately involved with CHEST and the CHEST Foundation for the last few years. Currently, he serves as the chair of the Practice Operations Network steering committee. Dr. Anjum is particularly interested in medical practice management and administration and hopes to continue sharing his knowledge through various platforms to help his fellow physicians.

Loren J. Harris, MD, FCCP – Board Member

Dr. Harris is the Chairman of the Department of Surgery and Chief of Thoracic Surgery at Richmond University Medical Center in Staten Island, NY. He has been in clinical surgical practice for more than 20 years and also has more than 20 years of experience teaching both medical students and surgical residents and fellows. In addition, he served as Program Director of the general surgery residency program at Maimonides

Medical Center from 2014 to 2017. Dr. Harris has published and presented throughout his career both nationally and internationally. His main research and clinical interests are in the appropriate staging and treatment of non-small cell lung cancer. He served as the Chair of the CHEST Marketing Committee; was the editor Pulmonary Perspectives; and is a co-author on two chapters in the most recent edition of the Diagnosis and

Management Guidelines for Lung Cancer published by CHEST in 2013. Dr. Harris has also received several prestigious awards including the CHEST Soffer Award for Editorial Excellence.

Aaron B. Holley, MD, FCCP – Section Editor, Pulmonary Perspectives®

Dr. Holley currently serves as the Program Director for the Pulmonary and Critical Care Medicine Fellowship at the Walter Reed National Military Medical Center. He is an Associate Professor of Medicine at the Uniformed Services University with an interest in pulmonary physiology, cardiopulmonary exercise, and lung function testing; and venous thromboembolism. Dr. Holley is a Distinguished CHEST Educator and serves the College as

a member of the Pulmonary Physiology Function and Rehabilitation Network, Airways Disorders Network, Pulmonary Physiology Domain Task Force, and the Guidelines Oversight Committee.

Diego Maselli, MD, FCCP – Board Member

Dr. Maselli is an Associate Professor of Medicine in the Division of Pulmonary Diseases & Critical Care Medicine at UT Health in San Antonio. He is the director of the Severe Asthma Program at UT Health and his research focuses on severe asthma, COPD, and bronchiectasis. Dr. Maselli has been designated a Distinguished CHEST Educator since 2017 when the program was initiated. He serves on the steering committee of the Airways Network.

Daniel R. Ouellette, MD, FCCP – Section Editor, Critical Care Commentary

Dr. Ouellette has been a clinician, teacher, and researcher in pulmonary and critical care medicine for 35 years. He is currently a Senior Staff Physician at Henry Ford Hospital in Detroit where he is the Medical Director for the Pulmonary Ward. He is

also an Associate Clinical Professor of Medicine at the Wayne State University School of Medicine, and the Medical Director of the Respiratory Therapy program at Oakland Community College. Dr. Ouellette has over 20 years of military service and was the Consultant to the US Army Surgeon General for Pulmonary Medicine during the last several years of his military career. An active CHEST leader, he has chaired the Guideline Oversight Committee, the Clinical

Pulmonary Network, and the Council of Governors, has been a member of the Board of Regents, and held many leadership roles with CHEST and other societies in the development of evidence-based clinical practice guidelines. Dr. Ouellette's clinical areas of interest include general pulmonary and critical care medicine and evidence-based practice.

Saiprakash Venkateshiah, MD, FCCP – Board Member

Dr. Venkateshiah is an Associate Professor of Medicine in the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine at Emory University, Atlanta, GA. He is a clinician educator and a “general pulmonologist” practicing the entire gamut of pulmonary, critical care, and sleep medicine. Dr. Venkateshiah has been a CHEST member for close to 2 decades. He has been involved with CHEST NetWork leadership since

2012, starting as steering committee member of Clinical Pulmonary Medicine Network transitioning to Vice-Chair and Chair. He was previously a member of the Executive Committee of the Council of Networks and the Scientific Program Committee for CHEST 2019 and CHEST 2020. He is currently a steering committee member of the education committees of CHEST and American Academy of Sleep Medicine. He is also a steering committee member of the CHEST Sleep NetWork. ■

informally shared among transplant programs – have raised the specter of more severe dysfunction following the acute phase and more early CLAD, said Tathagat Narula, MD, assistant professor of medicine at the Mayo Medical School, Rochester, Minn., and a consultant in lung transplantation at the Mayo Clinic’s Jacksonville, Fla., program.

“The available data cover only 3-6 months out. We don’t know what will happen in the next 6 months and beyond,” Dr. Narula said in an interview.

The risks of COVID-19 in already-transplanted patients and issues relating to the inadequate antibody responses to vaccination are just some of the challenges of lung transplant medicine in the era of SARS-CoV-2. “COVID-19,” said Dr. Narula, “has completely changed the way we practice lung transplant medicine – the way we’re looking both at our recipients and our donors.”

Potential donors are being evaluated with lower respiratory SARS-CoV-2 testing and an abundance of caution. And patients with severe COVID-19 affecting their own lungs are roundly expected to drive up lung transplant volume in the near future. “The whole paradigm has changed,” Dr. Narula said.

Postacute trajectories

A chart review study published in October (*Transpl Infect Dis.* 2021 Oct 4. doi: 10.1111/tid.13739) by the lung transplant team at the University of Texas Southwestern Medical Center, Dallas, covered 44 consecutive survivors at a median follow-up of 4.5 months from hospital discharge or acute illness (the survival rate was 83.3%). Patients had significantly impaired functional status, and 18 of the 44 (40.9%) had a significant and persistent loss of forced vital capacity or forced expiratory volume in 1 second (>10% from pre-COVID-19 baseline).

Three patients met the criteria for new CLAD after COVID-19 infection, with all three classified as restrictive allograft syndrome (RAS) phenotype.

Moreover, the majority of COVID-19 survivors who had CT chest scans (22 of 28) showed persistent parenchymal opacities – a finding that, regardless of symptomatology, suggests persistent allograft injury, said Amit Banga, MD, associate professor of medicine and medical director of the ex vivo lung perfusion program in UT Southwestern’s lung transplant program.

“The implication is that there

may be long-term consequences of COVID-19, perhaps related to some degree of ongoing inflammation and damage,” said Dr. Banga, a coauthor of the postinfection outcomes paper.

The UT Southwestern lung transplant program, which normally performs 60-80 transplants a year, began routine CT scanning 4-5 months into the pandemic, after “stumbling into a few patients who had no symptoms indicative of COVID pneumonia and no changes on an x-ray but significant involvement on a CT,” he said.

COVID-19 has proven to be far worse for lung transplant recipients than illness with other respiratory viruses, including RSV. “Patients have more frequent and greater loss of lung function, and worse debility from the acute illness.”

Without routine scanning in the general population of COVID-19 patients, Dr. Banga noted, “we’re limited in convincingly saying that COVID is uniquely doing this to lung transplant recipients.” Nor can they conclude that SARS-CoV-2 is unique from other respiratory viruses such as respiratory syncytial virus (RSV) in this regard. (The program has added CT scanning to its protocol for lung transplant recipients afflicted with other respiratory viruses to learn more.)

However, in the big picture, COVID-19 has proven to be far worse for lung transplant recipients than illness with other respiratory viruses, including RSV. “Patients have more frequent and greater loss of lung function, and worse debility from the acute illness,” Dr. Banga said.

“The cornerstones of treatment of both these viruses are very similar, but both the in-hospital course and the postdischarge outcomes are significantly different.”

In an initial paper published in September 2021, Dr. Banga and colleagues compared their first 25 lung transplant patients testing positive for SARS-CoV-2 with a historical cohort of 36 patients with RSV treated during 2016-2018.

Patients with COVID-19 had significantly worse morbidity and mortality, including worse postinfection lung function loss, functional decline, and 3-month survival (*J Heart Lung Transplant.* 2021;40[9]:936-47).

More time, he said, will shed light

on the risks of CLAD and the long-term potential for recovery of lung function. Currently, at UT Southwestern, it appears that patients who survive acute illness and the “first 3-6 months after COVID-19, when we’re seeing all the postinfection morbidity, may [enter] a period of stability,” Dr. Banga said.

Overall, he said, patients in their initial cohort are “holding steady” without unusual morbidity, readmissions, or “other setbacks to their allografts.”

At the Mayo Clinic in Jacksonville, which normally performs 40-50 lung transplants a year, transplant physicians have similarly observed significant declines in lung function beyond the acute phase of COVID-19.

“Anecdotally, we’re seeing that some patients are beginning to recover some of their lung function, while others have not,” said Dr. Narula. “And we don’t have predictors as to who will progress to CLAD. It’s a big knowledge gap.”

Dr. Narula noted that patients with restrictive allograft syndrome, such as those reported by the UT Southwestern team, “have scarring of the lung and a much worse prognosis than the obstructive type of chronic rejection.” Whether there’s a role for antifibrotic therapy is a question worthy of research.

In UT Southwestern’s analysis, persistently lower absolute lymphocyte counts (< 600/dL) and

higher ferritin levels (>150 ng/mL) at the time of hospital discharge were independently associated with significant lung function loss. This finding, reported in their October paper, has helped guide their management practices, Dr. Banga said.

“Persistently elevated ferritin may indicate ongoing inflammation at the allograft level,” he said. “We now send [such patients] home on a longer course of oral corticosteroids.”

At the front end of care for infected lung transplant recipients, Dr. Banga said that his team and physicians at other lung transplant programs are holding the cell-cycle inhibitor component of patients’ maintenance immunosuppression therapy (commonly mycophenolate or azathioprine) once infection is diagnosed to maximize chances of a better outcome.

“There may be variation on how long [the regimens are adjusted],” he said. “We changed our duration from 4 weeks to 2 due to patients developing a rebound worsening in the third and fourth week of acute illness.”

There is significant variation from institution to institution in how viral infections are managed in lung transplant recipients, he and Dr. Narula said. “Our numbers are so small in lung transplant, and we don’t have standardized protocols – it’s one of the biggest challenges in our field,” said Dr. Narula.

Continued on following page

Daniel R. Oullette, MD, FCCP, comments: I am not a lung transplantation doctor. Sure, I studied immunosuppressive regimens and post-transplantation infectious complications last year when I re-certified in pulmonary medicine, but I leave the day-to-day management of these complex patients to my lung transplantation colleagues who are experts. I do refer my patients for transplantation, though. One of my patients, a man in his mid-50s with hypersensitivity pneumonitis, took me on a journey for several years through dyspnea and abnormal x-rays, lung biopsies, corticosteroids, and finally domiciliary oxygen. The robust guy who played hockey with his friends at 50 on frozen Michigan lakes a few years later couldn’t walk across the room without gasping for breath. His lung transplantation gave him a new lease on life and a trip to Disneyland with his kids.

Our lung transplantation patients face a new threat from COVID-19. In addition to being at risk for acute infection and severe disease because of their immune-compromised status, we now learn that there may be insidious long-term effects from even apparently innocuous infection. Researchers are finding that patients have new and chronic changes on imaging studies and may have accelerated forms of rejection. We need to learn more about how to effectively vaccinate patients on complex immunosuppressive regimens. I hope that we surmount these problems so that our patients who have been transplanted successfully may continue to enjoy their renewed good quality of life.



Sputum biomarkers may predict COPD exacerbations

BY WALTER ALEXANDER

MDedge News

FROM THE JOURNAL CHEST® ■ Examining sputum from patients with chronic obstructive pulmonary disease may help predict the course of the disease.

A mass spectrometric panel of biomarkers related to mucus hydration and inflammation examined in sputa showed elevated levels of metabolites from multiple pathways in patients with COPD. These correlated with sputum neutrophil counts and COPD exacerbations. In particular, sialic acid and hypoxanthine concentrations were strongly associated with

disease severity, according to a study reported in the journal CHEST (doi: 10.1016/j.chest.2021.10.049), authored by Charles R. Esther Jr. MD, PhD, and colleagues.

Given that an improved understanding of the pathways associated with airway pathophysiology in COPD will identify new predictive biomarkers and novel therapeutic targets, Dr. Esther and colleagues posed the question: Which physiologic pathways are altered and predict exacerbations in the airways of subjects with COPD?

They noted that in persons with COPD – characterized by dominant small-airway obstruction associated

with airway inflammation – multiple inflammatory pathways, as well as indices of oxidative stress (including oxidized glutathione and 8-iso-prostane), are elevated in sputum. Because inflammation is a challenging therapeutic target, identification of other biologic pathways involved in COPD pathogenesis could point to novel biomarkers and therapeutic targets.

Using this approach in cystic fibrosis (CF), the authors have previously identified small-molecule metabolites correlated with airway inflammation. Findings from that research supported development of a mass spectrometric

biomarker panel for simultaneous measurement of inflammatory markers coupled to biomarkers of mucus hydration. The researchers applied this technology to sputum supernatants collected through the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), which included subjects with COPD, as well as relevant smoking and nonsmoking controls.

Addressing inflammation

“Inhaled steroids are really more effective for allergic inflammation as in asthma and less so for the neutrophilic inflammation that dominates

Continued on following page

Transplantation *continued from previous page*

Vaccination issues, evaluation of donors

Whether or not immunosuppression regimens should be adjusted prior to vaccination is a controversial question, but is “an absolutely valid one” and is currently being studied in at least one National Institutes of Health-funded trial involving solid organ transplant recipients, said Dr. Wolfe.

“Some have jumped to the conclusion [based on some earlier data] that they should reduce immunosuppression regimens for everyone at the time of vaccination ... but I don’t know the answer yet,” he said. “Balancing staying rejection free with potentially gaining more immune response is complicated ... and it may depend on where the pandemic is going in your area and other factors.”

Reductions aside, Dr. Wolfe tells lung transplant recipients that, based on his approximation of a number of different studies in solid organ transplant recipients, approximately 40%-50% of patients who are immunized with two doses of the COVID-19 mRNA vaccines will develop meaningful antibody levels – and that this rises to 50%-60% after a third dose.

It is difficult to glean from available studies the level of vaccine response for lung transplant recipients specifically. But given that their level of maintenance immunosuppression is higher than for recipients of other donor organs, “as a broad sweep, lung transplant recipients tend to be lower in the pecking order of response,” he said.

Still, “there’s a lot to gain,” he said, pointing to a recent study from the Morbidity and Mortality Weekly

Report (2021 Nov 5. doi: 10.15585/mmwr.mm7044e3) showing that effectiveness of mRNA vaccination against COVID-19-associated hospitalization was 77% among immunocompromised adults (compared with 90% in immunocompetent adults).

“This is good vindication to keep vaccinating,” he said, “and perhaps speaks to how difficult it is to assess the vaccine response [through measurement of antibody only].”

Neither Duke University’s transplant program, which performed 100-120 lung transplants a year pre-COVID, nor the programs at UT Southwestern or the Mayo Clinic in Jacksonville require that solid organ transplant candidates be vaccinated against SARS-CoV-2 in order to receive transplants, as some other transplant programs have done. (When asked about the issue, Dr. Banga and Dr. Narula each said that they have had no or little trouble convincing patients awaiting lung transplants of the need for COVID-19 vaccination.)

In an August statement, the American Society of Transplantation recommended vaccination for all solid organ transplant recipients, preferably prior to transplantation, and said that it “support[s] the development of institutional policies regarding pretransplant vaccination.”

The Society is not tracking centers’ vaccination policies. But Kaiser Health News reported in October that a growing number of transplant programs, such as UCHHealth in Denver and UW Medicine in Seattle, have decided to either bar patients who refuse to be vaccinated from receiving transplants or give them lower priority on waitlists.

Potential lung donors, meanwhile,

must be evaluated with lower respiratory COVID-19 testing, with results available prior to transplantation, according to policy developed by the Organ Procurement and Transplantation Network and effective in May 2021. The policy followed three published cases of donor-derived COVID-19 in lung transplant recipients, said Dr. Wolfe, who wrote about use of COVID-positive donors in an editorial published in October (*Transpl Infect Dis.* 2021;23[5]:e13727).

In each case, the donor had a negative COVID-19 nasopharyngeal swab at the time of organ procurement but was later found to have the virus on bronchoalveolar lavage, he said.

(The use of other organs from COVID-positive donors is appearing thus far to be safe, Dr. Wolfe noted. In the editorial, he references 13 cases of solid organ transplantation from SARS-CoV-2-infected donors into noninfected recipients; none of the 13 transplant recipients developed COVID-19).

Some questions remain, such as how many lower respiratory tests should be run, and how donors should be evaluated in cases of discordant results. Dr. Banga shared the case of a donor with one positive lower respiratory test result followed by two negative results. After internal debate, and consideration of potential false positives and other issues, the team at UT Southwestern decided to decline the donor, Dr. Banga said.

Other programs are likely making similar, appropriately cautious decisions, said Dr. Wolfe. “There’s no way in real-time donor evaluation to know whether the positive test is active virus that could infect the

recipient and replicate ... or whether it’s [picking up] inactive or dead fragments of virus that was there several weeks ago. Our tests don’t differentiate that.”

Transplants in COVID-19 patients

Decision-making about lung transplant candidacy among patients with COVID-19 acute respiratory distress syndrome is complex and in need of a new paradigm.

“Some of these patients have the potential to recover, and they’re going to recover way later than what we’re used to,” said Dr. Banga. “We can’t extrapolate for COVID ARDS what we’ve learned for any other virus-related ARDS.”

Dr. Narula also has recently seen at least one COVID-19 patient on ECMO and under evaluation for transplantation recover. “We do not want to transplant too early,” he said, noting that there is consensus that lung transplant should be pursued only when the damage is deemed irreversible clinically and radiologically in the best judgment of the team. Still, “for many of these patients the only exit route will be lung transplants. For the next 12-24 months, a significant proportion of our lung transplant patients will have had post-COVID-related lung damage.”

As of October 2021, 233 lung transplants had been performed in the United States in recipients whose primary diagnosis was reported as COVID related, said Anne Paschke, media relations specialist with the United Network for Organ Sharing.

Dr. Banga, Dr. Wolfe, and Dr. Narula reported that they have no relevant disclosures. ■

in COPD. The challenge is that neutrophilic inflammation is also a key response to infection, and it's really hard to find an anti-inflammatory that suppresses neutrophilic inflammation well enough to get clinical benefit but not so much that the patient becomes vulnerable to infection. Lots of clinical trials of anti-inflammatories in cystic fibrosis or COPD have been stopped because treated subjects had more trouble with infection," Dr. Esther stated in an interview,

The investigators analyzed cell-free sputum supernatants from 980 subjects, including samples from 77 healthy nonsmokers (NS), 341 ever-smokers with preserved spirometry (SPS), and 562 subjects with COPD (178 GOLD [Global Initiative for Chronic Obstructive Lung Disease]1, 303 GOLD 2, and 81 GOLD 3). Among the subjects with COPD, elevated biomarkers from multiple pathways correlated with sputum neutrophil counts.

The most significant analytes (at FDR [False Discovery Rate] 0.1) were sialic acid (a mucin marker), hypoxanthine, xanthine, methylthioadenosine, adenine, and glutathione, with sialic acid and hypoxanthine strongly associated with measures of disease severity. Elevation of sialic acid and hypoxanthine were associated with shorter time to exacerbation and improved prediction models of future exacerbations.

Study results

Sialic acid was elevated in all GOLD groups relative to NS healthy controls, with a 2.8-fold (0.44 log) increase in GOLD 2 and 3.7 fold (0.56 log) increase in GOLD 3 relative to NS. Sialic acid was also elevated in the most severe disease cohorts (GOLD 2 and GOLD 3) relative to smokers with preserved spirometry (SPS) and those with less severe disease (GOLD 1).

Within the full cohort, both sialic acid and hypoxanthine were significantly elevated in those who had multiple (two or more) pulmonary exacerbations relative to those who had none ($P = .001$). Similar findings were observed for xanthine ($P = .01$), methylthioadenosine ($P = .01$), adenine ($P = .01$), and glutathione ($P = .01$).

Sputum tests needed

While tests still need to be developed, Dr. Esther noted in an interview that they would be based on well-established technologies commonly utilized in clinical laboratories. "Sputum biomarkers of mucus hydration and adenosine metabolism could help clinicians predict which

patients with COPD are likely to experience multiple pulmonary exacerbations. Tests would be applied to patients with COPD at higher risk for exacerbations; for example, those who have low lung function or a history of prior exacerbations."

Dr. Esther noted that these biomarkers could be helpful in developing novel therapies. "Using sialic acid


to assess mucus concentrations is much easier than other methods, so it could help in developing mucolytic treatments. Also, adenosine metabolism represents a novel therapeutic target in COPD. Drugs that modify adenosine metabolism that have been approved for other diseases such as gout could be tested in COPD. As with mucus hydration, the biomark-

ers we identified (particularly hypoxanthine) could be utilized to make sure that novel therapies are having the intended impact on airway adenosine metabolism."

The research was supported by SPIROMICS (funded by NIH and the COPD Foundation). Dr. Esther reported having no relevant disclosures. ■



- 1 The treatment of IPF
- 2 The treatment of chronic fibrosing ILDs with a progressive phenotype
- 3 Slowing the rate of decline in pulmonary function in patients with SSc-ILD



Experience adds up with OFEV

ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; SSc-ILD, systemic sclerosis-associated interstitial lung disease.

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

Hepatic Impairment: OFEV is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment. Patients with mild hepatic impairment (Child Pugh A) can be treated with a reduced dosage (100 mg twice daily). Consider treatment interruption or discontinuation for management of adverse reactions.

Elevated Liver Enzymes and Drug-Induced Liver Injury

- Cases of drug-induced liver injury (DILI) have been observed with OFEV treatment. In the clinical trials and post-marketing period, non-serious and serious cases of DILI were reported. Cases of severe liver injury with fatal outcome have been reported in the post-marketing period. The majority of hepatic events occur within the first three months of treatment. OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, and GGT) and bilirubin. Liver enzyme and bilirubin increases were reversible with dose modification or interruption in the majority of cases.
- In IPF studies, the majority (94%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (95%) of patients with bilirubin elevations had elevations less than 2 times ULN.
- In the chronic fibrosing ILDs with a progressive phenotype study, the majority (95%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (94%) of patients with bilirubin elevations had elevations less than 2 times ULN.

The Pfizer antiviral is only for people who test positive for coronavirus and who are at high risk for severe COVID-19, including hospitalization or death.

Other therapies to treat the infection are available – monoclonal antibodies and the drug remdesivir – but

they are given by infusion.

The updated analysis of the Merck pill's effectiveness showed 48 hospitalizations or deaths among study participants who were randomly assigned to take the antiviral drug, compared with 68 among those who took a placebo.


Those results come from the full set of 1,433 patients who were randomized in the clinical trial, which just became available last week.

Initial results from the first 775 patients enrolled in the clinical trial, which were issued in a company news release in October, had said

the drug cut the risk of hospitalization or death for patients at high risk of severe disease by about 50%.

Merck has been producing millions of doses of molnupiravir, which is the first antiviral pill to treat COVID-19 infections. The

Continued on following page



See how the clinical trial data adds up at [OFEVhcp.com/experience](https://www.ofevhcp.com/experience)

**IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS (CONT'D)**

Elevated Liver Enzymes and Drug-Induced Liver Injury (cont'd)

- In the SSc-ILD study, a maximum ALT and/or AST greater than or equal to 3 times ULN was observed in 4.9% of patients treated with OFEV.
- Patients with low body weight (less than 65 kg), patients who are Asian, and female patients may have a higher risk of elevations in liver enzymes. Nintedanib exposure increased with patient age, which may result in increased liver enzymes.
- Conduct liver function tests prior to initiation of treatment, at regular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. Measure liver function tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Dosage modifications, interruption, or discontinuation may be necessary for liver enzyme elevations.

Please see additional Important Safety Information on the following pages and accompanying Brief Summary of Prescribing Information.

United Kingdom's drug regulator authorized use of the medication in early November. The company said it expected to distribute the medication globally by the end of 2021.

In October, two Indian drug companies halted late-stage clinical trials of a generic version of molnupiravir after the studies failed to find any

benefit to patients with moderate COVID-19. Trials in patients with milder symptoms are still ongoing.

The medication is designed to be given as four pills taken every 12 hours for 5 days. It's most effective when taken within the first few days of new symptoms, something that requires convenient, affordable testing.

The new results seem to put

molnupiravir far below the effectiveness of existing treatments. The infused monoclonal antibody cocktail REGEN-COV, which the FDA has already authorized for emergency use, is about 85% effective at preventing hospitalization or death in patients who are at risk for severe COVID-19 outcomes, and it appears to be

just as effective in people who already have antibodies against COVID-19, which is why it is being given to both vaccinated and unvaccinated patients, the FDA said.

In early November, Pfizer said its experimental antiviral pill Paxlovid cut the risk of hospitalization or death by 89%.

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT'D)

Gastrointestinal Disorders

Diarrhea

- Events were primarily mild to moderate in intensity and occurred within the first 3 months.
- In IPF studies, diarrhea was the most frequent gastrointestinal event reported in 62% versus 18% of patients treated with OFEV and placebo, respectively. Diarrhea led to permanent dose reduction in 11% and discontinuation in 5% of OFEV patients versus 0 and less than 1% in placebo patients, respectively.
- In the chronic fibrosing ILDs with a progressive phenotype study, diarrhea was reported in 67% versus 24% of patients treated with OFEV and placebo, respectively. Diarrhea led to permanent dose reduction in 16% and discontinuation in 6% of OFEV patients, compared to less than 1% of placebo-treated patients, respectively.
- In the SSc-ILD study, diarrhea was the most frequent gastrointestinal event reported in 76% versus 32% of patients treated with OFEV and placebo, respectively. Diarrhea led to permanent dose reduction in 22% and discontinuation in 7% of OFEV patients versus 1% and 0.3% in placebo patients, respectively.
- Dosage modifications or treatment interruptions may be necessary in patients with diarrhea. Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider dose reduction or treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists, discontinue treatment.

Nausea and Vomiting

- In IPF studies, nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
- In the chronic fibrosing ILDs with a progressive phenotype study, nausea was reported in 29% versus 9% and vomiting was reported in 18% versus 5% of patients treated with OFEV and placebo, respectively. Nausea led to discontinuation of OFEV in less than 1% of patients, and vomiting led to discontinuation of OFEV in 1% of the patients.
- In the SSc-ILD study, nausea was reported in 32% versus 14% and vomiting was reported in 25% versus 10% of patients treated with OFEV and placebo, respectively. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
- In most patients, events were primarily of mild to moderate intensity. If nausea or vomiting persists despite appropriate supportive care including anti-emetic therapy, consider dose reduction or treatment interruption. OFEV treatment may be resumed at full dosage or at reduced dosage, which subsequently may be increased to full dosage. If severe nausea or vomiting does not resolve, discontinue treatment.

Embryo-Fetal Toxicity: OFEV can cause fetal harm when administered to a pregnant woman and patients should be advised of the potential risk to a fetus. Women should be advised to avoid becoming pregnant while receiving OFEV and to use highly effective contraception at initiation of treatment, during treatment, and at least 3 months after the last dose of OFEV. Nintedanib does not change the exposure to oral contraceptives containing ethinylestradiol and levonorgestrel in patients with SSc-ILD. However, the efficacy of oral hormonal contraceptives may be compromised by vomiting and/or diarrhea or other conditions where drug absorption may be reduced. Advise women taking oral hormonal contraceptives experiencing these conditions to use alternative highly effective contraception. Verify pregnancy status prior to starting OFEV and during treatment as appropriate.

Arterial Thromboembolic Events

- In IPF studies, arterial thromboembolic events were reported in 2.5% of OFEV and less than 1% of placebo patients, respectively. Myocardial infarction (MI) was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and in less than 1% of placebo patients.
- In the chronic fibrosing ILDs with a progressive phenotype study, arterial thromboembolic events and MI were reported in less than 1% of patients in both treatment arms.
- In the SSc-ILD study, arterial thromboembolic events were reported in 0.7% of patients in both the OFEV-treated and placebo-treated patients. There were 0 cases of MI in OFEV-treated patients compared to 0.7% of placebo-treated patients.
- Use caution when treating patients at higher cardiovascular risk, including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

Risk of Bleeding

- OFEV may increase the risk of bleeding.
- In IPF studies, bleeding events were reported in 10% of OFEV versus 7% of placebo patients.
- In the chronic fibrosing ILDs with a progressive phenotype study, bleeding events were reported in 11% of OFEV versus 13% of placebo patients.
- In the SSc-ILD study, bleeding events were reported in 11% of OFEV versus 8% of placebo patients.
- In clinical trials, epistaxis was the most frequent bleeding event. There have been post-marketing reports of non-serious and serious bleeding events, some of which were fatal. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk.

Gastrointestinal Perforation

- OFEV may increase the risk of gastrointestinal perforation.
- In IPF studies, gastrointestinal perforation was reported in less than 1% of OFEV versus in 0% of placebo patients.

“This was clearly a difficult decision [on molnupiravir],” said advisory committee member Michael Green, MD, a pediatric infectious disease expert at the University of Pittsburgh School of Medicine. Dr. Green said he voted yes, and that the drug’s ability to prevent deaths in the study weighed heavily on his decision.

He said given uncertainties around the drug, both the company and FDA should keep a close eye on patients taking the drug going forward.

Others didn’t agree that the drug should be allowed onto the market.

“I voted no,” said Jennifer Le, PharmD, a professor of clinical pharmacy at the University of Cali-

fornia. Dr. Le said the modest benefit of the medication didn’t outweigh all the potential safety issues. “I think I just need more efficacy and safety data,” she said.

“The efficacy of this product is not overwhelmingly good,” said committee member David Hardy, MD, an infectious disease expert at Charles Drew University School of

Medicine in Los Angeles.

“And I think that makes all of us a little uncomfortable about whether this is an advanced therapeutic because it’s an oral medication rather than an intravenous medication,” he said during the panel’s deliberations.

“I think we have to be very careful about how we’re going to allow people to use this,” Dr. Hardy said. ■

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT’D)

Gastrointestinal Perforation (cont’d)

- In the chronic fibrosing ILDs with a progressive phenotype study, gastrointestinal perforation was not reported in any treatment arm.
- In the SSc-ILD study, no cases of gastrointestinal perforation were reported in either OFEV or placebo-treated patients.
- In the post-marketing period, cases of gastrointestinal perforations have been reported, some of which were fatal. Use caution when treating patients who have had recent abdominal surgery, have a previous history of diverticular disease, or who are receiving concomitant corticosteroids or NSAIDs. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

ADVERSE REACTIONS

- Most common adverse reactions reported (greater than or equal to 5%) are diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decreased and hypertension.
- In IPF studies, the most frequent serious adverse reactions reported in patients treated with OFEV, more than placebo, were bronchitis (1.2% vs. 0.8%) and MI (1.5% vs. 0.4%). The most common adverse events leading to death in OFEV patients versus placebo were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV versus 1.8% in placebo patients.
- In the chronic fibrosing ILDs with a progressive phenotype study, the most frequent serious adverse event reported in patients treated with OFEV, more than placebo, was pneumonia (4% vs. 3%). Adverse events leading to death were reported in 3% of OFEV patients and in 5% of placebo patients. No pattern was identified in the adverse events leading to death.
- In the SSc-ILD study, the most frequent serious adverse events reported in patients treated with OFEV, more than placebo, were interstitial lung disease (2.4% vs. 1.7%) and pneumonia (2.8% vs. 0.3%). Within 52 weeks, 5 patients treated with OFEV (1.7%) and 4 patients treated with placebo (1.4%) died. There was no pattern among adverse events leading to death in either treatment arm.

DRUG INTERACTIONS

- **P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers:** Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of potent P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John’s wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib.
- **Anticoagulants:** Nintedanib may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary.

USE IN SPECIFIC POPULATIONS

- **Nursing Mothers:** Because of the potential for serious adverse reactions in nursing infants from OFEV, advise women that breastfeeding is not recommended during treatment.
- **Reproductive Potential:** OFEV may reduce fertility in females of reproductive potential.
- **Smokers:** Smoking was associated with decreased exposure to OFEV, which may affect the efficacy of OFEV. Encourage patients to stop smoking prior to and during treatment.

CL-OF-100050 10.28.2020

Please see accompanying Brief Summary of Prescribing Information on the following pages.

References: 1. OFEV® (nintedanib) Prescribing Information, Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2020. 2. Data on file. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. December 2020.



Copyright ©2021, Boehringer Ingelheim Pharmaceuticals, Inc.
All rights reserved. (03/21) PC-US-120066A



Study: Atezolizumab plus chemo bests supportive care

BY WALTER ALEXANDER
MDedge News

The 34% reduction in disease recurrence for adjuvant atezolizumab in PD-L1 tumor

cells of at least 50% stage II-IIIa patients in the IMpower010 clinical trial, may change the standard of care for early-stage non-small cell lung cancer (NSCLC), according to Enriqueta Felip, MD, the head of

thoracic and head and neck cancer unit at Vall d'Hebron Institute of Oncology, Hospital, Barcelona.

IMpower010 is the first positive randomized phase 3 study to show significant disease-free survival

(DFS) improvement with adjuvant cancer immunotherapy (atezolizumab, anti-programmed death-ligand 1 (PDL-1), and platinum-based chemotherapy) in this population, Dr. Felip said in a presentation at the

OFEV® (nintedanib) capsules, for oral use BRIEF SUMMARY OF PRESCRIBING INFORMATION.

Please see package insert for full Prescribing Information, including Patient Information

1 INDICATIONS AND USAGE: 1.1 Idiopathic Pulmonary Fibrosis: OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). **1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype:** OFEV is indicated for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. **1.3 Systemic Sclerosis-Associated Interstitial Lung Disease:** OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

2 DOSAGE AND ADMINISTRATION: 2.1 Testing Prior to OFEV Administration: Conduct liver function tests in all patients and a pregnancy test in females of reproductive potential prior to initiating treatment with OFEV [see Warnings and Precautions]. **2.2 Recommended Dosage:** The recommended dosage of OFEV is 150 mg twice daily administered approximately 12 hours apart. OFEV capsules should be taken with food and swallowed whole with liquid. OFEV capsules should not be chewed or crushed because of a bitter taste. The effect of chewing or crushing of the capsule on the pharmacokinetics of nintedanib is not known. If a dose of OFEV is missed, the next dose should be taken at the next scheduled time. Advise the patient to not make up for a missed dose. Do not exceed the recommended maximum daily dosage of 300 mg. In patients with mild hepatic impairment (Child Pugh A), the recommended dosage of OFEV is 100 mg twice daily administered approximately 12 hours apart taken with food. **2.3 Dosage Modification due to Adverse Reactions:** In addition to symptomatic treatment, if applicable, the management of adverse reactions of OFEV may require dose reduction or temporary interruption until the specific adverse reaction resolves to levels that allow continuation of therapy. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If a patient does not tolerate 100 mg twice daily, discontinue treatment with OFEV [see Warnings and Precautions and Adverse Reactions]. Dose modifications or interruptions may be necessary for liver enzyme elevations. Conduct liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin) prior to initiation of treatment with OFEV, at regular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. Discontinue OFEV in patients with AST or ALT greater than 3 times the upper limit of normal (ULN) with signs or symptoms of liver injury and for AST or ALT elevations greater than 5 times the upper limit of normal. For AST or ALT greater than 3 times to less than 5 times the ULN without signs of liver damage, interrupt treatment or reduce OFEV to 100 mg twice daily. Once liver enzymes have returned to baseline values, treatment with OFEV may be reintroduced at a reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage (150 mg twice daily) [see Warnings and Precautions and Adverse Reactions]. In patients with mild hepatic impairment (Child Pugh A), consider treatment interruption, or discontinuation for management of adverse reactions.

4 CONTRAINDICATIONS: None

5 WARNINGS AND PRECAUTIONS: 5.1 Hepatic Impairment: Treatment with OFEV is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment [see Use in Specific Populations]. Patients with mild hepatic impairment (Child Pugh A) can be treated with a reduced dose of OFEV [see Dosage and Administration]. **5.2 Elevated Liver Enzymes and Drug-Induced Liver Injury:** Cases of drug-induced liver injury (DILI) have been observed with OFEV treatment. In the clinical trials and postmarketing period, non-serious and serious cases of DILI were reported. Cases of severe liver injury with fatal outcome have been reported in the postmarketing period. The majority of hepatic events occur within the first three months of treatment. In clinical trials, administration of OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, GGT) and bilirubin. Liver enzyme and bilirubin increases were reversible with dose modification or interruption in the majority of cases. In IPF studies

(Studies 1, 2, and 3), the majority (94%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (95%) of patients with bilirubin elevations had elevations less than 2 times ULN. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), the majority (95%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN and the majority (94%) of patients with bilirubin elevations had elevations less than 2 times ULN. In the SSc-ILD study (Study 4), a maximum ALT and/or AST greater than or equal to 3 times ULN was observed for 4.9% of patients in the OFEV group and for 0.7% of patients in the placebo group [see Use in Specific Populations]. Patients with a low body weight (less than 65 kg), Asian, and female patients may have a higher risk of elevations in liver enzymes. Nintedanib exposure increased with patient age, which may also result in a higher risk of increased liver enzymes. Conduct liver function tests (ALT, AST, and bilirubin) prior to initiation of treatment with OFEV, at regular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. Dosage modifications or interruption may be necessary for liver enzyme elevations. [see Dosage and Administration]. **5.3 Gastrointestinal Disorders:**

Diarrhea: In clinical trials, diarrhea was the most frequent gastrointestinal event reported. In most patients, the event was of mild to moderate intensity and occurred within the first 3 months of treatment. In IPF studies (Studies 1, 2, and 3), diarrhea was reported in 62% versus 18% of patients treated with OFEV and placebo, respectively [see Adverse Reactions]. Diarrhea led to permanent dose reduction in 11% of patients treated with OFEV compared to 0 placebo-treated patients. Diarrhea led to discontinuation of OFEV in 5% of the patients compared to less than 1% of placebo-treated patients. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), diarrhea was reported in 67% versus 24% of patients treated with OFEV and placebo, respectively [see Adverse Reactions]. Diarrhea led to permanent dose reduction in 16% of patients treated with OFEV compared to less than 1% of placebo-treated patients. Diarrhea led to discontinuation of OFEV in 6% of the patients compared to less than 1% of placebo-treated patients. In the SSc-ILD study (Study 4), diarrhea was reported in 76% versus 32% of patients treated with OFEV and placebo, respectively [see Adverse Reactions]. Diarrhea led to permanent dose reduction in 22% of patients treated with OFEV compared to 1% of placebo-treated patients. Diarrhea led to discontinuation of OFEV in 7% of the patients compared to 0.3% of placebo-treated patients. Dosage modifications or treatment interruptions may be necessary in patients with adverse reactions of diarrhea. Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider treatment interruption if diarrhea continues [see Dosage and Administration]. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists despite symptomatic treatment, discontinue treatment with OFEV. **Nausea and Vomiting:** In IPF studies (Studies 1, 2, and 3), nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), nausea was reported in 29% versus 9% and vomiting was reported in 18% versus 5% of patients treated with OFEV and placebo, respectively. In the SSc-ILD study (Study 4), nausea was reported in 25% versus 10% of patients treated with OFEV and placebo, respectively [see Adverse Reactions]. In most patients, these events were of mild to moderate intensity. In IPF studies (Studies 1, 2, and 3), nausea led to discontinuation of OFEV in 2% of patients and vomiting led to discontinuation of OFEV in 1% of the patients. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), nausea led to discontinuation of OFEV in less than 1% of patients and vomiting led to discontinuation of OFEV in 1% of the patients. In the SSc-ILD study (Study 4), nausea led to discontinuation of OFEV in 2% of patients and vomiting led to discontinuation of OFEV in 1% of the patients. For nausea or vomiting that persists despite appropriate supportive care including anti-emetic therapy, dose reduction or treatment interruption may be required [see Dosage and Administration]. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage

(100 mg twice daily), which subsequently may be increased to the full dosage. If severe nausea or vomiting does not resolve, discontinue treatment with OFEV. **5.4 Embryo-Fetal Toxicity:** Based on findings from animal studies and its mechanism of action, OFEV can cause fetal harm when administered to a pregnant woman. Nintedanib caused embryo-fetal deaths and structural abnormalities in rats and rabbits when administered during organogenesis at less than (rats) and approximately 5 times (rabbits) the maximum recommended human dose (MRHD) in adults. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to avoid becoming pregnant while receiving treatment with OFEV and to use highly effective contraception at initiation of, during treatment, and at least 3 months after the last dose of OFEV. Nintedanib does not change the exposure to oral contraceptive containing ethinylestradiol and levonorgestrel in patients with SSc-ILD. However, the efficacy of oral hormonal contraceptives may be compromised by vomiting and/or diarrhea or other conditions where the drug absorption may be reduced. Advise women taking oral hormonal contraceptives experiencing these conditions to use alternative highly effective contraception. Verify pregnancy status prior to treatment with OFEV and during treatment as appropriate [see Use in Specific Populations]. **5.5 Arterial Thromboembolic Events:** Arterial thromboembolic events have been reported in patients taking OFEV. In IPF studies (Studies 1, 2, and 3), arterial thromboembolic events were reported in 2.5% of patients treated with OFEV and 0.8% of placebo-treated patients. Myocardial infarction was the most common adverse reaction under arterial thromboembolic events, occurring in 1.5% of OFEV-treated patients compared to 0.4% of placebo-treated patients. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), arterial thromboembolic events were reported in less than 1% of patients in both treatment arms. Myocardial infarction was observed in less than 1% of patients in both treatment arms. In the SSc-ILD study (Study 4), arterial thromboembolic events were reported in 0.7% of patients in both treatment arms. There were 0 cases of myocardial infarction in OFEV-treated patients compared to 0.7% of placebo-treated patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia. **5.6 Risk of Bleeding:** Based on the mechanism of action (VEGFR inhibition), OFEV may increase the risk of bleeding. In IPF studies (Studies 1, 2, and 3), bleeding events were reported in 10% of patients treated with OFEV and in 7% of patients treated with placebo. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), bleeding events were reported in 11% of patients treated with OFEV and in 13% of patients treated with placebo. In the SSc-ILD study (Study 4), bleeding events were reported in 11% of patients treated with OFEV and in 8% of patients treated with placebo. In the postmarketing period non-serious and serious bleeding events, some of which were fatal, have been observed. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk. **5.7 Gastrointestinal Perforation:** Based on the mechanism of action, OFEV may increase the risk of gastrointestinal perforation. In IPF studies (Studies 1, 2, and 3), gastrointestinal perforation was reported in 0.3% of patients treated with OFEV, compared to 0 cases in the placebo-treated patients. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), gastrointestinal perforation was not reported in any patients in any treatment arm. In the SSc-ILD study (Study 4), no cases of gastrointestinal perforation were reported in patients treated with OFEV or in placebo-treated patients. In the postmarketing period, cases of gastrointestinal perforations have been reported, some of which were fatal. Use caution when treating patients who have had recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

6 ADVERSE REACTIONS: The following adverse reactions are discussed in greater detail in other sections of the labeling: Elevated Liver Enzymes and Drug-Induced Liver Injury [see Warnings and Precautions]; Gastrointestinal Disorders [see Warnings and Precautions]; Embryo-Fetal Toxicity [see Warnings and Precautions]; Arterial Thromboembolic Events [see Warnings and Precautions]; Risk of Bleeding [see Warnings and Precautions];

2021 European Society for Medical Oncology Congress on Sept. 20, 2021 (abstract LBA9).

High unmet need

Up to 60% of patients with stage I-III NSCLC still experience disease relapse despite having received treatment, Dr. Felip said. IMPower010 included 1,280 patients who

received up to four cycles of chemotherapy (cisplatin with pemetrexed, gemcitabine, docetaxel, or vinorelbine) after completely resected stage IB-III NSCLC. Patients were randomized to open label to atezolizumab (1,200 mg every 21 days for 16 cycles or best supportive care (BSC). The primary endpoint of investigator-assessed DFS in the

stage II-III population (n = 1,005) was stratified according to three groups: PD-L1 tumor cells of at least 1% (stage II-III), all-randomized (stage II-III) and intention-to-treat (stage IB-III).

Median disease-free survival in PD-L1 tumor cells of at least 1% was not estimated in the atezolizumab group and was 35.3 months in the BSC

group (95% CI, 29.0 to NE). In the all-randomized group, median DFS was 42.3 months in the atezolizumab group (95% CI, 36.0 to NE) and 35.3 months in the BSC group (95% CI, 30.4-46.4) with a stratified hazard ratio of 0.79 (95% CI, 0.64-0.96; P = .02). In the intent-to-treat population, median DFS was not evaluable in the

Continued on following page

Gastrointestinal Perforation [see Warnings and Precautions]. **6.1 Clinical Trials Experience:** Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of OFEV was evaluated in over 1000 IPF patients, 332 patients with chronic fibrosing ILDs with a progressive phenotype, and over 280 patients with SSc-ILD. Over 200 IPF patients were exposed to OFEV for more than 2 years in clinical trials. **Idiopathic Pulmonary Fibrosis:** OFEV was studied in three randomized, double-blind, placebo-controlled, 52-week trials. In the phase 2 (Study 1) and phase 3 (Studies 2 and 3) trials, 723 patients with IPF received OFEV 150 mg twice daily and 508 patients received placebo. The median duration of exposure was 10 months for patients treated with OFEV and 11 months for patients treated with placebo. Subjects ranged in age from 42 to 89 years (median age of 67 years). Most patients were male (79%) and Caucasian (60%). The most frequent serious adverse reactions reported in patients treated with OFEV, more than placebo, were bronchitis (1.2% vs. 0.8%) and myocardial infarction (1.5% vs. 0.4%). The most common adverse events leading to death in patients treated with OFEV, more than placebo, were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV-treated patients and 1.8% of placebo-treated patients. Adverse reactions leading to permanent dose reductions were reported in 16% of OFEV-treated patients and 1% of placebo-treated patients. The most frequent adverse reaction that led to permanent dose reduction in the patients treated with OFEV was diarrhea (11%). Adverse reactions leading to discontinuation were reported in 21% of OFEV-treated patients and 15% of placebo-treated patients. The most frequent adverse reactions that led to discontinuation in OFEV-treated patients were diarrhea (5%), nausea (2%), and decreased appetite (2%). The most common adverse reactions with an incidence of greater than or equal to 5% and more frequent in the OFEV than placebo treatment group are listed in Table 1.

Table 1 Adverse Reactions Occurring in ≥5% of OFEV-treated Patients and More Commonly Than Placebo in Studies 1, 2, and 3

Adverse Reaction	OFEV, 150 mg n=723	Placebo n=508
Gastrointestinal disorders		
Diarrhea	62%	18%
Nausea	24%	7%
Abdominal pain ^a	15%	6%
Vomiting	12%	3%
Hepatobiliary disorders		
Liver enzyme elevation ^b	14%	3%
Metabolism and nutrition disorders		
Decreased appetite	11%	5%
Nervous system disorders		
Headache	8%	5%
Investigations		
Weight decreased	10%	3%
Vascular disorders		
Hypertension ^c	5%	4%

^a Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain and abdominal tenderness.

^b Includes gamma-glutamyltransferase increased, hepatic enzyme increased, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic function abnormal, liver function test abnormal, transaminase increased, blood alkaline phosphatase-increased, alanine aminotransferase abnormal, aspartate aminotransferase abnormal, and gamma-glutamyltransferase abnormal.

^c Includes hypertension, blood pressure increased, hypertensive crisis, and hypertensive cardiomyopathy.

In addition, hypothyroidism was reported in patients treated with OFEV, more than placebo (1.1% vs. 0.6%). **Combination with Pirfenidone:** Concomitant treatment with nintedanib and pirfenidone was investigated in an exploratory open-label, randomized (1:1) trial of nintedanib 150 mg twice daily with add-on pirfenidone (titrated to 801 mg three times a day) compared to nintedanib 150 mg twice daily alone in 105 randomized patients for 12 weeks. The

primary endpoint was the percentage of patients with gastrointestinal adverse events from baseline to Week 12. Gastrointestinal adverse events were in line with the established safety profile of each component and were experienced in 37 (70%) patients treated with pirfenidone added to nintedanib versus 27 (53%) patients treated with nintedanib alone. Diarrhea, nausea, vomiting, and abdominal pain (includes upper abdominal pain, abdominal discomfort, and abdominal pain) were the most frequent adverse events reported in 20 (38%) versus 16 (31%), in 22 (42%) versus 6 (12%), in 15 (28%) versus 6 (12%) patients, and in 15 (28%) versus 7 (14%) treated with pirfenidone added to nintedanib versus nintedanib alone, respectively. More subjects reported AST or ALT elevations (greater than or equal to 3x the upper limit of normal) when using pirfenidone in combination with nintedanib (n=3 (6%)) compared to nintedanib alone (n=0) [see Warnings and Precautions]. **Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype:** OFEV was studied in a phase 3, double-blind, placebo-controlled trial (Study 5) in which 663 patients with chronic fibrosing ILDs with a progressive phenotype were randomized to receive OFEV 150 mg twice daily (n=332) or placebo (n=331) for at least 52 weeks. At 52 weeks, the median duration of exposure was 12 months for patients in both treatment arms. Subjects ranged in age from 27 to 87 years (median age of 67 years). The majority of patients were Caucasian (74%) or Asian (25%). Most patients were male (54%). The most frequent serious adverse event reported in patients treated with OFEV, more than placebo, was pneumonia (4% vs. 3%). Adverse events leading to death were reported in 3% of patients treated with OFEV and in 5% of patients treated with placebo. No pattern was identified in the adverse events leading to death. Adverse reactions leading to permanent dose reductions were reported in 33% of OFEV-treated patients and 4% of placebo-treated patients. The most frequent adverse reaction that led to permanent dose reduction in the patients treated with OFEV was diarrhea (16%). Adverse reactions leading to discontinuation were reported in 20% of OFEV-treated patients and 10% of placebo-treated patients. The most frequent adverse reaction that led to discontinuation in OFEV-treated patients was diarrhea (6%). The safety profile in patients with chronic fibrosing ILDs with a progressive phenotype treated with OFEV was consistent with that observed in IPF patients. In addition, the following adverse events were reported in OFEV more than placebo in chronic progressive fibrosing ILD: nasopharyngitis (13% vs. 12%), upper respiratory tract infection (7% vs. 6%), urinary tract infection (6% vs. 4%), fatigue (10% vs. 6%), and back pain (6% vs. 5%). **Systemic Sclerosis-Associated Interstitial Lung Disease:** OFEV was studied in a phase 3, randomized, double-blind, placebo-controlled trial (Study 4) in which 576 patients with SSc-ILD received OFEV 150 mg twice daily (n=288) or placebo (n=288). Patients were to receive treatment for at least 52 weeks; individual patients were treated for up to 100 weeks. The median duration of exposure was 15 months for patients treated with OFEV and 16 months for patients treated with placebo. Subjects ranged in age from 20 to 79 years (median age of 55 years). Most patients were female (75%). Patients were mostly Caucasian (67%), Asian (25%), or Black (6%). At baseline, 49% of patients were on stable therapy with mycophenolate. The most frequent serious adverse events reported in patients treated with OFEV, more than placebo, were interstitial lung disease (2.4% nintedanib vs 1.7% placebo) and pneumonia (2.8% nintedanib vs 0.3% placebo). Within 52 weeks, 5 patients treated with OFEV (1.7%) and 4 patients treated with placebo (1.4%) died. There was no pattern among adverse events leading to death in either treatment arm. Adverse reactions leading to permanent dose reductions were reported in 34% of OFEV-treated patients and 4% of placebo-treated patients. The most frequent adverse reaction that led to permanent dose reduction in the patients treated with OFEV was diarrhea (22%). Adverse reactions leading to discontinuation were reported in 16% of OFEV-treated patients and 9% of placebo-treated patients. The most frequent adverse reactions that led to discontinuation in OFEV-treated patients were diarrhea (7%), nausea (2%), vomiting (1%), abdominal pain (1%), and interstitial lung disease (1%). The safety profile in patients with or without mycophenolate at baseline was comparable. The most common adverse reactions with an incidence of greater than or equal to 5% in OFEV-treated patients and more commonly than in placebo are listed in Table 2.

Table 2 Adverse Reactions Occurring in ≥5% of OFEV-treated Patients and More Commonly Than Placebo in Study 4

Adverse Reaction	OFEV, 150 mg n=288	Placebo n=288
Diarrhea	76%	32%
Nausea	32%	14%
Vomiting	25%	10%
Skin ulcer	18%	17%
Abdominal pain ^a	18%	11%
Liver enzyme elevation ^b	13%	3%
Weight decreased	12%	4%
Fatigue	11%	7%
Decreased appetite	9%	4%
Headache	9%	8%
Pyrexia	6%	5%
Back pain	6%	4%
Dizziness	6%	4%
Hypertension ^c	5%	2%

^a Includes abdominal pain, abdominal pain upper, abdominal pain lower, and esophageal pain.

^b Includes alanine aminotransferase increased, gamma-glutamyltransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, blood alkaline phosphatase increased, transaminase increased, and hepatic function abnormal.

^c Includes hypertension, blood pressure increased, and hypertensive crisis

6.2 Postmarketing Experience: The following adverse reactions have been identified during postapproval use of OFEV. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during postapproval use of OFEV: drug-induced liver injury [see Warnings and Precautions], non-serious and serious bleeding events, some of which were fatal [see Warnings and Precautions], pancreatitis, thrombocytopenia, rash, pruritus.

7 DRUG INTERACTIONS: 7.1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers: Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4. Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV [see Dosage and Administration]. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John's wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib. **7.2 Anticoagulants:** Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary [see Warnings and Precautions]. **7.3 Pirfenidone:** In a multiple-dose study conducted to assess the pharmacokinetic effects of concomitant treatment with nintedanib and pirfenidone, the coadministration of nintedanib with pirfenidone did not alter the exposure of either agent. Therefore, no dose adjustment is necessary during concomitant administration of nintedanib with pirfenidone. **7.4 Bosentan:** Coadministration of nintedanib with bosentan did not alter the pharmacokinetics of nintedanib.

8 USE IN SPECIFIC POPULATIONS: 8.1 Pregnancy: Risk Summary: Based on findings from animal studies and its mechanism of action, OFEV can cause fetal harm when administered to a pregnant woman. There are no data on the use of OFEV during pregnancy. In animal studies of pregnant rats and rabbits treated during organogenesis, nintedanib caused embryo-fetal deaths and structural abnormalities at less than (rats) and approximately 5 times (rabbits) the maximum recommended human dose [see Data]. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and

atezolizumab group and 37.2 months in the BSC group (95% CI, 31.6 to NE) with a hazard ratio of 0.81 (95% CI, 0.67-0.99; $P = .04$).

DFS hazard ratio 0.43 in the tumor cells $\geq 50\%$ group

Looking at DFS by PD-L1 status in the population with and with-

out known EGFR/ALK+ disease, Dr. Felip said that the hazard ratio for the tumor cells of at least 50% group ($n = 229$) was 0.43 (95% CI, 0.27-0.68), as compared with 0.87 (95% CI, 0.60-1.26) for the tumor cells 1%-49% group. With EGFR/ALK+ patients excluded, the respective HRs were similar (0.43/0.82). Considering DFS

events including only disease recurrence, disease incidence was 29.4% and 44.7% in the atezolizumab and BSC groups, respectively for those with PD-L1 tumor cells of at least 1%. The same pattern of atezolizumab benefit persisted in the all-randomized and intent-to-treat groups.

An assessment according to

regions of relapse (locoregional only, distant only, locoregional and distant, CNS only, second primary lung) revealed no differences in the three groups. Analysis of time from randomization to relapse revealed regional differences in the PD-L1 tumor cells of at least 1% group with a median time to any relapse of 17.6 months in the atezolizumab group and 10.9 months in the BSC group. Time from randomization to relapse was generally similar for atezolizumab and best supportive

“The greatest magnitude of disease-free survival benefit was observed in the PD-L1 tumor cell of at least 50% population with a hazard ratio of 0.43.”

care in the all randomized and intent-to-treat groups (about 11-12 months).

“The greatest magnitude of disease-free survival benefit was observed in the PD-L1 tumor cell of at least 50% population with a hazard ratio of 0.43,” Dr. Felip said. In a post hoc analysis excluding patients with known EGFR/ALK with NSCLC, she said that hazard ratios were numerically improved in most PD-L1 subgroups.

Postrelapse cancer immunotherapies were used at a higher rate in the BSC arm of the trial. “Longer-term follow-up is warranted and may reveal differences in relapse patterns and treatment options.”

Playing with the immune system

Benjamin Besse, MD, director of oncology and chair of the EO-RTC Lung Group at Paris-Saclay University, acknowledged the disease-free survival benefit with atezolizumab in IMpower010 and underscored that adjuvant immunotherapy has been changing treatment in resected cancers across tumor types (i.e., melanoma, renal cell carcinoma, NS-CLC).

He voiced some concerns, including the absence of benefit in PD-L1 less than 1%, pneumonectomy and EGFRmut/ALK+ patients, and generally the potential “when you play with the immune system for there to be a dark side too.”

Dr. Besse said delayed side effects in 43.2% of patients, citing a recent report of chronic, mostly grade 1-2 immune-related adverse

Continued on following page

miscarriage in clinically recognized pregnancies is 15% to 20%. **Data: Animal Data:** In animal reproduction toxicity studies, nintedanib caused embryo-fetal deaths and structural abnormalities in rats and rabbits at less than and approximately 5 times the maximum recommended human dose (MRHD) in adults (on a plasma AUC basis at maternal oral doses of 2.5 and 15 mg/kg/day in rats and rabbits, respectively). Malformations included abnormalities in the vasculature, urogenital, and skeletal systems. Vasculature anomalies included missing or additional major blood vessels. Skeletal anomalies included abnormalities in the thoracic, lumbar, and caudal vertebrae (e.g., hemivertebra, missing, or asymmetrically ossified), ribs (bifid or fused), and sternbrae (fused, split, or unilaterally ossified). In some fetuses, organs in the urogenital system were missing. In rabbits, a significant change in sex ratio was observed in fetuses (female:male ratio of approximately 71%:29%) at approximately 15 times the MRHD in adults (on an AUC basis at a maternal oral dose of 60 mg/kg/day). Nintedanib decreased post-natal viability of rat pups during the first 4 post-natal days when dams were exposed to less than the MRHD (on an AUC basis at a maternal oral dose of 10 mg/kg/day). **8.2 Lactation: Risk Summary:** There is no information on the presence of nintedanib in human milk, the effects on the breast-fed infant or the effects on milk production. Nintedanib and/or its metabolites are present in the milk of lactating rats [see Data]. Because of the potential for serious adverse reactions in nursing infants from OFEV, advise women that breastfeeding is not recommended during treatment with OFEV. **Data:** Milk and plasma of lactating rats have similar concentrations of nintedanib and its metabolites. **8.3 Females and Males of Reproductive Potential:** Based on findings from animal studies and its mechanism of action, OFEV can cause fetal harm when administered to a pregnant woman and may reduce fertility in females of reproductive potential [see Use in Specific Populations]. Counsel patients on pregnancy prevention and planning. **Pregnancy Testing:** Verify the pregnancy status of females of reproductive potential prior to treatment with OFEV and during treatment as appropriate. [see Dosage and Administration, Warnings and Precautions and Use in Specific Populations]. **Contraception:** OFEV can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to avoid becoming pregnant while receiving treatment with OFEV. Advise females of reproductive potential to use highly effective contraception at initiation of, during treatment, and for at least 3 months after taking the last dose of OFEV. Nintedanib does not change the exposure to oral contraceptive containing ethinylestradiol and levonorgestrel in patients with SSc-ILD. However, the efficacy of oral hormonal contraceptives may be compromised by vomiting and/or diarrhea or other conditions where the drug absorption may be reduced. Advise women taking oral hormonal contraceptives experiencing these conditions to use alternative highly effective contraception. **Infertility:** Based on animal data, OFEV may reduce fertility in females of reproductive potential. **8.4 Pediatric Use:** Safety and effectiveness in pediatric patients have not been established. **8.5 Geriatric Use:** Of the total number of subjects in phase 2 and 3 clinical studies of OFEV in IPF, 60.8% were 65 and over, while 16.3% were 75 and over. In the chronic fibrosing ILDs with a progressive phenotype clinical study (Study 5), 61% were 65 and over, while 19% were 75 and older. In SSc-ILD, 21.4% were 65 and over, while 1.9% were 75 and older. In phase 3 studies, no overall differences in effectiveness were observed between subjects who were 65 and over and younger subjects; no overall differences in safety were observed between subjects who were 65 and over or 75 and over and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. **8.6 Hepatic Impairment:** Nintedanib is predominantly eliminated via biliary/fecal excretion (greater than 90%). In a PK study performed in patients with hepatic impairment (Child Pugh A, Child Pugh B), exposure to nintedanib was increased. In patients with mild hepatic impairment (Child Pugh A), the recommended dosage of OFEV is 100 mg twice daily [see Dosage and Administration]. Monitor for adverse reactions and consider treatment interruption, or discontinuation for management of adverse reactions in these patients [see Dosage and Administration]. Treatment of patients with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment with OFEV is not recommended [see Warnings and Precautions]. **8.7 Renal Impairment:** Based on a single-dose study, less than 1% of the total dose of nintedanib is excreted via

the kidney. Adjustment of the starting dose in patients with mild to moderate renal impairment is not required. The safety, efficacy, and pharmacokinetics of nintedanib have not been studied in patients with severe renal impairment (less than 30 mL/min CrCl) and end-stage renal disease.

8.8 Smokers: Smoking was associated with decreased exposure to OFEV, which may alter the efficacy profile of OFEV. Encourage patients to stop smoking prior to treatment with OFEV and to avoid smoking when using OFEV.

10 OVERDOSAGE: In IPF trials, one patient was inadvertently exposed to a dose of 600 mg daily for a total of 21 days. A non-serious adverse event (nasopharyngitis) occurred and resolved during the period of incorrect dosing, with no onset of other reported events. Overdose was also reported in two patients in oncology studies who were exposed to a maximum of 600 mg twice daily for up to 8 days. Adverse events reported were consistent with the existing safety profile of OFEV. Both patients recovered. In case of overdose, interrupt treatment and initiate general supportive measures as appropriate.

17 PATIENT COUNSELING INFORMATION: Advise the patient to read the FDA-approved patient labeling (Patient Information). **Elevated Liver Enzymes and Drug-Induced Liver Injury:** Advise patients that they will need to undergo liver function testing periodically. Advise patients to immediately report any symptoms of a liver problem (e.g., skin or the whites of eyes turn yellow, urine turns dark or brown (tea colored), pain on the right side of stomach, bleed or bruise more easily than normal, lethargy, loss of appetite) [see Warnings and Precautions]. **Gastrointestinal Disorders:** Inform patients that gastrointestinal disorders such as diarrhea, nausea, and vomiting were the most commonly reported gastrointestinal events occurring in patients who received OFEV. Advise patients that their healthcare provider may recommend hydration, antidiarrheal medications (e.g., loperamide), or anti-emetic medications to treat these side effects. Temporary dosage reductions or discontinuations may be required. Instruct patients to contact their healthcare provider at the first signs of diarrhea or for any severe or persistent diarrhea, nausea, or vomiting [see Warnings and Precautions and Adverse Reactions]. **Embryo-Fetal Toxicity:** Counsel patients on pregnancy prevention and planning. Advise females of reproductive potential of the potential risk to a fetus and to avoid becoming pregnant while receiving treatment with OFEV. Advise females of reproductive potential to use highly effective contraception at initiation of, during treatment, and for at least 3 months after taking the last dose of OFEV. Advise women taking oral hormonal contraceptives who experience vomiting and/or diarrhea or other conditions where the drug absorption may be reduced to contact their doctor to discuss alternative highly effective contraception. Advise female patients to notify their doctor if they become pregnant or suspect they are pregnant during therapy with OFEV [see Warnings and Precautions and Use in Specific Populations]. **Arterial Thromboembolic Events:** Advise patients about the signs and symptoms of acute myocardial ischemia and other arterial thromboembolic events and the urgency to seek immediate medical care for these conditions [see Warnings and Precautions]. **Risk of Bleeding:** Bleeding events have been reported. Advise patients to report unusual bleeding [see Warnings and Precautions]. **Gastrointestinal Perforation:** Serious gastrointestinal perforation events have been reported. Advise patients to report signs and symptoms of gastrointestinal perforation [see Warnings and Precautions]. **Lactation:** Advise patients that breastfeeding is not recommended while taking OFEV [see Use in Specific Populations]. **Smokers:** Encourage patients to stop smoking prior to treatment with OFEV and to avoid smoking when using OFEV. **Administration:** Instruct patients to take OFEV with food, to swallow OFEV capsules whole with liquid, and not to chew or crush the capsules due to the bitter taste. Advise patients to not make up for a missed dose [see Dosage and Administration].

Copyright © 2020 Boehringer Ingelheim International GmbH
ALL RIGHTS RESERVED

COL9114AJ192020 (10/20)

CL-OF-100053



Boehringer
Ingelheim

Apixaban outmatches rivaroxaban for VTE in study

BY WILL PASS

MDedge News

Apixaban appears to be safer and more effective than rivaroxaban for reducing risk of venous thromboembolism and bleeding, based on new research.

Recurrent venous thromboembolism (VTE) – a composite of pulmonary embolism and deep vein thrombosis – was the primary effectiveness outcome in the retrospective analysis of new-user data from almost 40,000 patients, which was published in *Annals of Internal Medicine* (2021 Dec 6. doi: 10.7326/M21-0717). Safety was evaluated through a composite of intracranial and gastrointestinal bleeding.

After a median follow-up of 102 days in the apixaban group and 105 days in the rivaroxaban group, apixaban demonstrated superiority for both primary outcomes. These real-world findings may guide selection of initial anticoagulant therapy, reported lead author Ghadeer K. Dawwas, PhD, MSc, MBA, of the University of Pennsylvania, Philadelphia, and colleagues.

“Randomized clinical trials comparing apixaban with rivaroxaban in patients with VTE are under way (for example, COBRRA (NCT03266783),” the investigators wrote.

“Until the results from these trials become available (The estimated completion date for COBRRA is December 2023.), observational studies that use existing data can provide evidence on the effectiveness and safety of these alternatives to inform clinical practice.”

In the new research, apixaban was associated with a 23% lower rate of recurrent VTE (hazard ratio, 0.77; 95% confidence interval, 0.69-0.87), including a 15% lower rate of deep vein thrombosis and a 41% lower rate of pulmonary embolism.

Apixaban was associated with 40% fewer bleeding events (HR, 0.60; 95% CI, 0.53-0.69), including a 40% lower rate of GI bleeding and a 46% lower rate of intracranial bleeding.

The study involved 37,236 patients with VTE, all of whom were diagnosed in at least one inpatient encounter and initiated direct oral anticoagulant (DOAC) therapy within 30 days, according to Optum’s deidentified Clinformatics Data Mart Database. Patients were evenly split into apixaban and rivaroxaban groups, with 18,618 individuals in each. Propensity score matching was used to minimize differences in baseline characteristics.

Apixaban was associated with an absolute reduction in recurrent VTE of 0.6% and 1.1% over 2 and 6 months, respectively, as well as reductions in bleeding of 1.1% and 1.5% over the same respective time periods.

The investigators noted that these findings were

maintained in various sensitivity and subgroup analyses, including a model in which patients with VTE who had transient risk factors were compared with VTE patients exhibiting chronic risk factors.

“These findings suggest that apixaban has superior effectiveness and safety, compared with rivaroxaban and may provide guidance to clinicians and patients regarding selection of an anticoagulant for treatment of VTE,” Dr. Dawwas and colleagues concluded.

Thomas Wakefield, MD, a vascular surgeon and a professor of surgery at the University of Michigan Health Frankel Cardiovascular Center, Ann Arbor, generally agreed with the investigators’ conclusion, although he noted that DOAC selection may also be influenced by other considerations.

“The results of this study suggest that, when choosing an agent for an individual patient,



“Hopefully this analysis will encourage more payers to create financial incentives that facilitate the use of apixaban in more patients.”

Dr. Damon E. Houghton

apixaban does appear to have an advantage over rivaroxaban related to recurrent VTE and bleeding,” Dr. Wakefield said in an interview.

“One must keep in mind that these are not the only factors that are considered when choosing an agent and these are not the only two DOACs available. For example, rivaroxaban is given once per day while apixaban is given twice per day, and rivaroxaban has been shown to be successful in the treatment of other thrombotic disorders.”

Dr. Wakefield also pointed out that the study may have missed some nuance in outcomes.

“The current study looked at severe outcomes that resulted in inpatient hospitalization, so the generalization to strictly outpatient treatment and less severe outcomes cannot be inferred,” he said.

Damon E. Houghton, MD, of the department of medicine and a consultant in the department of vascular medicine and hematology at Mayo Clinic, Rochester, Minn., called the study a “very nice analysis,” highlighting the large sample size.

“The results are not a reason to abandon rivaroxaban altogether, but do suggest that, when otherwise appropriate for a patient, apixaban should be the first choice,” Dr. Houghton said in a written comment. “Hopefully this analysis will encourage more payers to create financial incentives that facilitate the use of apixaban in more patients.”

Colleen Edwards, MD, of the departments of medicine, hematology, and medical oncology, at the Icahn School of Medicine at Mount Sinai, New York, had a more guarded view of the findings than Dr. Wakefield and Dr. Houghton.



“I think we really have to wait for randomized trial before we abandon our other choices.”

Dr. Colleen Edwards

“[The investigators] certainly seem to be doing a lot of statistical gymnastics in this paper,” Dr. Edwards said in an interview. “They used all kinds of surrogates in place of real data that you would get from a randomized trial.”

For example, Dr. Edwards noted the use of prescription refills as a surrogate for medication adherence, and emphasized that inpatient observational data may not reflect outpatient therapy.

“Inpatients are constantly missing their medicines all the time,” according to Dr. Edwards. “They’re holding it for procedures; they’re NPO; they’re off the floor, so they missed their medicine. So it’s just a very different patient population than the outpatient population, which is where venous thromboembolism is treated now, by and large.”

Although Dr. Edwards suggested that the findings might guide treatment selection “a little bit,” she noted that insurance constraints and costs play a greater role. “I think we really have to wait for randomized trial before we abandon our other choices,” she said.

The investigators disclosed relationships with Merck, Celgene, UCB, and others. Dr. Houghton and Dr. Edwards reported no relevant conflicts of interest. ■



Image shows a patient with pulmonary embolism.

CHEMO continued from previous page

events following (>12 weeks after discontinuation) adjuvant anti-PD-1 therapy for high-risk resected melanoma.

He mentioned, however, that the rate of second primary lung tumors in the atezolizumab group (1.4%)

was lower than in the BSC group (2.6%), with generally similar rates between immuno- and nonimmunotherapies in melanoma and breast cancer trials.

“IMpower 010 is the first adjuvant study establishing immune checkpoint blockade as a new standard of

care. We need to cure more, not to delay relapse,” he said. The optimal population for treatment is still yet to be defined, as is the best perioperative strategy, Dr. Besse added. “If approved I would prescribe adjuvant atezolizumab ... until I see the overall survival curves.”

IMpower010 was funded by F. Hoffmann–La Roche. Dr. Felip disclosed numerous financial interests, including having received financial support from F. Hoffmann–La Roche, AstraZeneca, Amgen, and Merck, among other pharmaceutical companies. ■

Poor pediatric asthma control tied to raised chance of COVID-19 hospitalization

BY HEIDI SPLETE

MDedge News

Children and adolescents with poorly controlled asthma were three to six times more likely to be hospitalized with COVID-19 infections, based on data from a national study of more than 750,000 children in Scotland.

Although the majority of COVID-19 cases in children have been mild, some children require hospitalization, wrote Ting Shi, PhD, of the University of Edinburgh and colleagues.

Vaccination policies to potentially reduce infection and hospitalization of children remain inconsistent, the researchers said. Identifying which school-age children would derive the greatest benefit from vaccination “could help to reduce the risk of infection and consequently the need for children to have time off school; and might also reduce the risk of spread of SARS-CoV-2 within schools and households.”

But the potential benefits of vaccination for children with asthma in particular have not been well studied, they wrote.

The United Kingdom’s Joint Commission on Vaccination and Immunisation commissioned research on the rates of hospitalization among children with poorly controlled asthma.

In a national incidence cohort study published in *The Lancet Respiratory Medicine* (2021 Nov 30. doi: 10.1016/S2213-2600[21]00491-4), the researchers reviewed data from all children aged 5-17 years in Scotland who were enrolled in the linked dataset of Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II).

The total number of children in the dataset was 752,867, and 63,463 (8.4%) of these had diagnosed asthma. Among the children with asthma, 4,339 (6.8%) had confirmed COVID-19 infections between March 1, 2020, and July 27, 2021. A total of 67 infected children were hospitalized. Of the

689,404 children without asthma, 40,231 (5.8%) had confirmed COVID-19 infections, and 382 (0.9%) of these children were hospitalized.

Overall, hospital admission rates for COVID-19 were significantly

Overall, hospital admission rates for COVID-19 were significantly higher among children with asthma, compared to those without asthma, and the rates increased among children with poorly controlled asthma.

higher among children with asthma, compared to those without asthma (adjusted hazard ratio, 1.49), and the rates increased among children with poorly controlled asthma.

The researchers used previous hospital admission for asthma as a measure of uncontrolled asthma, and found that hospitalization was at least six times as likely for children with poorly controlled asthma, compared with those with no asthma (aHR, 6.40), although children with well-controlled asthma also had an increased risk of hospitalization, compared with those with no asthma (aHR, 1.36).

When the researchers used oral corticosteroid prescriptions as an indicator of uncontrolled asthma, the adjusted hazard ratios were 3.38, 3.53, 1.52, and 1.34 for children with prescribed corticosteroid courses of three or more, two, one, and none, respectively, compared with children with no asthma.

These hazard ratios remained significant after controlling for factors including age, sex, socioeconomic status, comorbidity, and previous hospital admission, the researchers wrote.

In an age-based analysis, results were similar for children aged 12-17 years, but in children aged 5-11 years, the hospitalization risk decreased for those with one course of corticosteroids and reached the highest rate for those with three or more courses, rather than two courses.

The study findings were limited by several factors including

the relatively small numbers of COVID-19 hospitalizations, ICU admissions, and deaths in children with asthma, the researchers noted. Other limitations include potential changes in asthma control over the study period, and lack of data on certain confounders such as tobacco use, unsuitable housing, and ethnicity, they noted. However, the results were strengthened by the use of a large, national dataset, and access to electronic health records, they said.

The findings reflect data from previous studies suggesting increased risk of hospitalization for patients with respiratory illness who develop COVID-19 infections, the researchers wrote.

The results emphasize the importance of good asthma control to protect children from severe COVID-19, and careful monitoring of children with poorly controlled asthma who do become infected, they added.

“The findings from this linkage of multiple data sources have helped inform the prioritisation of school-aged children with poorly controlled asthma for vaccines,” they concluded.

Findings support value of vaccination for children with asthma

“Pediatricians see many children who suffer from asthma, and although one could assume that these children would have more serious consequences from contracting COVID-19, the current study examines a large database in a way not possible in the United States to address the severity question,” said Suzanne C. Boulter, MD, of the Geisel School of Medicine at Dartmouth, Hanover, N.H.

“The authors used prior hospitalization rate or two prescriptions for oral corticosteroids as markers of asthma severity prior to the onset of COVID-19 in Scotland, and they collected retrospective data for 16 months of the pandemic through July of 2021, showing a significant increase in hospitalization for those children,” she said. Dr. Boulter said she was not surprised by this finding, given the impact of COVID-19 on the respiratory system.

Continued on following page



Thoracic Radiology: Imaging for Clinicians

Key Topic Areas

- Basics of thoracic imaging
- Airways
- Infections
- Diffuse lung diseases
- Solitary and multiple nodules
- Pleura/mediastinum
- Pulmonary vasculature

NEW

The Only Clinical-Based Training Course in Chest Medicine

- See rare/unique cases that will deepen your knowledge base and take your thoracic imaging skills to the next level.
- Gain fuller understanding of thoracic disease states, so you can diagnose the disease and treat patients efficiently and effectively.
- Learn from CHEST’s expert faculty, practicing clinicians who speak from real experience and can provide in-depth perspectives.
- Study content any time it’s convenient for you.

chestnet.org/Thoracic-Radiology



This month in the journal *CHEST*[®]

Editor's picks

BY PETER J. MAZZONE, MD,
MPH, FCCP
Editor in Chief

Revisiting mild asthma: current knowledge and future needs.
By Dr. A. Mohan, et al.

Treatment of *Mycobacterium abscessus* pulmonary disease.
By Dr. D. Griffith, et al.

The utility of the rapid shallow breathing index in predicting successful extubation: A systematic review and meta-analysis.
By Dr. V. Trivedi, et al.

National temporal trends in hospitalization and inpatient mortality in patients with pulmonary sarcoidosis in the United States between 2007 – 2018.
By Dr. S. Alqalyoobi, et al.



How I Do It: Considering lung transplantation for patients with COVID-19.
By Dr. C. S. King, et al.

Addressing race in pulmonary function testing by aligning intent and evidence with practice and perception.
By Dr. N. Bhakta, et al.

ASTHMA *continued from previous page*

“Pediatricians have found significant challenges from some groups of parents when discussing the indications and need for vaccination in their patients,” said Dr. Boulter.

“Having this data on the increased risk of morbidity and mortality in

The results emphasize the importance of good asthma control to protect children from severe COVID-19, and careful monitoring of children with poorly controlled asthma who do become infected.

children with asthma might help parents who are uncertain about the risk/benefit ratio of the vaccine make their decision,” she said.

Dr. Boulter said she hoped that additional studies will yield ongoing information about hospitalization rates for COVID-19 not only about asthma, but also other diagnoses affecting children in the United States and worldwide.

“It would also be important to see a breakdown of ethnic factors and adverse childhood experiences and

how they relate to hospitalization and death from COVID-19,” Dr. Boulter said.

“The results of this study are not surprising, as we have known for a long time that children with severe asthma are more susceptible to severe respiratory viruses,” Francis E. Rushton, MD, a pediatrician in Beaufort, S.C., said in an interview.

“But the study is still important, as it helps us determine which children are most urgently in need of protection from COVID-19 in any of its forms,” he emphasized. In particular, the current study underlines the importance of vaccinating children with unstable asthma, Dr. Rushton said.

Going forward, “it would be interesting to do additional studies looking at other markers for poor asthma control that could guide our vaccine efforts so that they are focused on those most at risk,” he added.

The study was supported by the UK Research and Innovation (Medical Research Council), Research and Innovation Industrial Strategy Challenge Fund, Health Data Research UK, and the Scottish Government. Lead author Dr. Shi had no financial conflicts to disclose. Dr. Rushton and Dr. Boulter had no financial conflicts to disclose. ■

CHEST[®]
Congress
2022

Bologna
ITALY | 3-5 February



- Review relevant, engaging content from world-renowned faculty, bringing you the latest developments in chest medicine.
- Attend keynote lectures, including sessions in Italian, that convey our present scientific and technological revolution.
- Expand your knowledge, engage with international practitioners, and earn CME credits.

Register Now
congress.chestnet.org

IN PARTNERSHIP WITH THE
ITALIAN DELEGATION

Sleep disorders and cancer: It's complicated

BY RICHARD MARK KIRKNER

Sleep apnea and other types of sleep disorders appear to elevate the risk for some types of cancer, specifically prostate cancer, more so than others. But the overall risk can be highly variable, and some sleep problems were found to be associated with a lower risk for cancer and cancer-related death, an analysis of a large observational cohort study of cardiovascular patients found.

Results of the analysis were published online in the journal *Cancer Epidemiology* (2021 Nov 17. doi: 10.1016/j.canep.2021.102057). Investigators analyzed the presence of sleep apnea and insomnia and cancer risk in more than 8,500 patients in the Cardiovascular Health Study (CHS).

"The fact that we observed certain sleep problems, like apneas, to be associated with elevated risk of some cancers but not others reflects the fact that cancer is a heterogeneous disease," senior author Amanda Phipps, PhD, said in an interview. Dr. Phipps is an

associate professor of epidemiology at the University of Washington and the Fred Hutchinson Cancer Research Center, both in Seattle.

Variable cancer links

The researchers assessed sleep problems in two groups in the CHS: an incident cancer group of 3,930 patients and a cancer mortality group of 4,580 patients. Within those respective groups, the investigators identified 885 first-incident cancers and 804 cancer deaths with a median follow-up of 12 and 14 years. The average

age of the study population was 73 years, and 57% were women.

Sleep apnea symptoms (SAS) were associated with a lower risk for incident cancers – a 16% lower baseline risk and a 24% lower time-dependent risk. The study showed no association between cancer incidence and daytime sleepiness and apneas.

However, there was a significantly elevated risk relationship between sleep problems and prostate cancer. A time-dependent

analysis of apnea showed more than double the risk (hazard ratio, 2.34), and baseline snoring carried a 69% greater risk. There was also a dose-response relationship for baseline cumulative SAS, compared with not having symptoms: an HR of 1.30 for one symptom, and 2.22 for two or more symptoms.

Risks for lymphatic or hematopoietic cancers were also associated with baseline daytime sleepiness (HR, 1.81), but not with insomnia (HR, 0.54).

With regard to cancer mortality, the study found no relationship between sleep problems and cancer death. In fact, it found an overall inverse relationship with snoring (time-dependent HR, 0.73; cumulative average HR, 0.67) and baseline apnea (HR, 0.69).

Likewise, patients reporting SAS had lower risks than those having no SAS: an HR of 0.90 for one symptom and 0.75 for multiple symptoms. No relationships were found between any insomnia symptom and cancer death.

"We know the pathways that lead to prostate cancer can be very different than the pathways that lead to colorectal cancer," Dr. Phipps said. "What we don't yet understand is why these associations differ or what mechanisms

are responsible for these cancer site-specific associations."

Need for sleep assessment

The findings don't change much for how clinicians should evaluate cancer risks in patients with sleep problems, Dr. Phipps said.

"Other studies have clearly demonstrated the implications that sleep apnea has for a variety of other important health conditions – such as cardiovascular disease – so there are already plenty of good reasons for clinicians to ask their patients about their sleep and to connect patients with resources for the diagnosis and treatment of sleep apnea," she added. "This study provides another possible reason."

These findings provide context for future studies of the relationship between sleep problems and cancer. "But, given that sleep is something we all do and given that sleep problems are so pervasive, it's important that we keep trying to better understand this relationship," Dr. Phipps said.

"My hope is that future cancer studies will build in more detailed, longitudinal information on sleep patterns to help us fill current gaps in knowledge."

Dr. Phipps has disclosed no relevant financial relationships. ■

"The fact that we observed certain sleep problems, like apneas, to be associated with elevated risk of some cancers but not others reflects the fact that cancer is a heterogeneous disease."

Mary Jo Farmer, MD, PhD comments: Epidemiological papers are always interesting. Searching for possible associations in the dataset might set the stage for further research, whether at the bench or clinical setting.

The analysis published online in the *Journal of Cancer Epidemiology* uses the term "sleep problems" when identifying a significantly elevated risk relationship with prostate cancer. It is good that this term is more specifically defined as apnea, rather than baseline snoring. The presence of apnea more than doubled the cancer risk in a time-dependent analysis, while presence of baseline snoring carried a 69% greater risk of prostate cancer.

"Apnea" and "snoring" are terms that have specific meaning whereas "sleep problems" is nonspecific and harder to define, perhaps limiting the transferability of associations found in an epidemiologic analysis to further study at the bench or clinical level.

It is interesting to note that an association between prostate cancer in men and measures of intermittent hypoxia was also found in a study published in the *European*

Respiratory Journal (<https://erj.ersjournals.com/content/53/6/1900091>).

This study indicated a strong relationship between a cancer diagnosis and measures of intermittent hypoxia (ODI and CT90%) rather than AHI. The most prevalent cancer in women was breast cancer (43.8%), followed by gynecological (12.3%) and thyroid (6.9%) cancer, lymphoma (5.4%), lung (4.6%) and colon (3.1%) cancer, and melanoma (3.1%). The most prevalent cancer in males was prostate cancer (33.1%), followed by lymphoma (8.3%), colon cancer (8.3%), ear, nose, and throat cancer (8.3%), lung cancer (5.9%) and melanoma (5.3%). In a sub-analysis, there was no independent influence of OSA on the prevalence of breast and prostate cancer.

A letter to the editor points to some of the issues with database studies such as these: "There is growing, but debatable evidence for the potential association between obstructive sleep apnoea (OSA) and cancer. Available studies have reached contradictory conclusions due to limited sample sizes, and poor characterization of OSA phenotypes or type of malignancies (all types or site specific)."

The letter additionally pointed out that there were several hypotheses proposed for why carcinogenesis can occur in the context of OSA, including older age, sleep deprivation, and concomitant obesity.

It discussed how intermittent hypoxia and sleep fragmentation may also play a significant role via alterations in angiogenesis, sympathetic outflow, or modulation of immune function and tumor microenvironment.

"Gender-specific differences in the association between OSA and cancer prevalence have been poorly studied," the author added (DOI:10.1183/13993003.00091-2019).

Epidemiological studies such as these identify associations that require further investigation. If multiple epidemiological studies demonstrate an association between, for example, sleep apnea and prostate cancer in males, it could set the stage for exploration of these two conditions at the biological level to understand further associations and commonalities. ■



IN AN ONGOING STUDY, KOSMOS HAS BEEN SHOWN TO PRODUCE EQUIVALENT RESULTS TO LARGE CART-BASED SYSTEMS IN A MAJOR EUROPEAN HOSPITAL—INCLUDING A REDUCED NEED FOR ORDERING MORE ECHOS.



> echo queue



The use of the Kosmos ultrasound platform in acute care has been shown to reduce the ordering of in-house echos by over 90% in a longitudinal study covering now more than 2,000 patients.

The Us2.ai machine-learning tool has been validated to reduce echo processing time by 97%.

This combination can resolve the “waiting for the echo” problem in critical care—at a value greater than you’d expect.



Want to see for yourself? Scan the QR code to view the white paper and learn how Kosmos and Us2.ai can help your healthcare system optimize workflow.

Staying home, staying connected

Fundraising in a virtual environment

When the United States went into a 2-week quarantine to slow the spread of the COVID-19 coronavirus in March 2020, everything changed. In the months following, social distancing, working from home, and wearing masks became the norm, and life needed to find a way to go on.

The world adapted to a virtual environment, but some of the hardest hit by this change were non-profit organizations that relied on in-person contact to encourage donations that support their worthwhile missions.

This was even more challenging for the CHEST Foundation as our donors work on the front lines of the pandemic.

“It was important for us to not only stay engaged with our donors but also to recognize what those on the front lines are dealing with,” says Angela Perillo, Director, Development & Foundation Operations at the American College of Chest Physicians. “Through these events, we wanted to provide some

respite from the stresses of their long days.”

The CHEST Foundation is about championing lung health, and there was no greater awareness of the



need than now. It was time to get creative.

Viva la vino

A well-known “secret” is CHEST CEO Bob Mussachio’s love of wine, and he’s not alone in his passion for the grape. Perillo put this knowledge to good use creating a wine tasting series that took people around the world one bottle at a time.

The online Viva La Vino evening gatherings serve to bring donors together for a night of good wines

and good conversation. A benefit to the virtual wine nights is that no one has to travel but that it keeps the group together and keeps the Foundation at the forefront of most

everyone’s minds.

“I love attending the wine nights. They are so interesting, and I get to see people who don’t live in New York – it’s just great,” says regular participant Ilene (Lenie) Rosen.

The wines are shipped directly to the participants’ homes and during the online Zoom session, Mussachio guides the tasting by scrolling through a presentation on the wine’s background and what to expect from the taste. As the wines are tasted, the participants have a

chance to share their review.

“It’s always enthralling to me how much our members know about wine. It makes for a really fun evening listening to their critiques and even learning a bit myself. These events have provided a great platform to stay engaged with our donors and enjoy an evening at home with company,” says Perillo.

Doubling down on a good cause

After hosting its in-person event in March 2020, the Irv Feldman Texas Hold ’Em poker tournament shifted to a virtual environment to stay engaged with its players.

Supported by the CHEST Foundation, the Feldman Family Foundation created a series of poker tournaments through an online platform that worked with Zoom to retain the engagement offered by in-person events. Through the Zoom call, players are able to talk to each other either in the main room or in breakout rooms created for each table.

Continued on following page

Trailblazers of the Future.

25 YEARS


The CHEST Foundation 25th Anniversary Celebration continues!

Join us in 2022 as we navigate our next 25 years, and help us crush lung disease!

Every time you register for an event or make a donation, what you’re really doing is funding our initiatives—programs that enable patients to get access to the care they need. Help us fulfill our mission by joining an event in honor of the CHEST Foundation 25th Anniversary.



9th Annual Irv Feldman Texas Hold’Em Tournament and Casino Night
Saturday, April 9, 2022



NYC Belmont Reception and Auction
Saturday, June 11, 2022

Our events are fun. Our work is serious.



For more information
chestfoundation.org

Looking for more?

The Best-Selling SEEK Library Now Upgraded

NEW CHEST SEEK™ Library Plus

SEEK Library Plus gives you access to the **1,200+ questions** and **300+ CME/MOC/CE** found in the classic, comprehensive subscription level PLUS:

- **Board Review SEEK Sessions:** 3 video discussions of SEEK questions from CHEST Board Review 2021
- **SEEK Peer Review Discussions:** 6 behind-the-scenes videos
- **30 Years of SEEK:** 30 favorite questions over the 30-year history
- **SEEK Study Pack:** 75 perennially popular questions, with a print export option

Purchase Now chestnet.org/seeklibrary

275 New Questions

The SEEK Library now has **125 new Sleep Medicine Collection** questions and **150 new Pulmonary Medicine Collection** questions.



Repositioning CHEST Networks for the future

Angel Coz, MD, FCCP, Chair, Council of Networks

Cassie Kennedy, MD, FCCP, Vice-Chair, Council of Networks

Aneesa Das, MD, FCCP, Co-Chair, Networks Task Force

David Zielinski, MD, FCCP, Co-Chair, Networks Task Force



Dr. Coz



Dr. Kennedy



Dr. Das



Dr. Zielinski

Welcome to the new year and your new Networks structure.

We are excited to introduce the updated approach that will address the evolving needs of the Networks.

This transition has been more than 2 years in the making. In 2019, under the directive of former CHEST President, Dr. Stephanie Levine, the Networks Task Force was charged with guiding a redevelopment plan with the goal of better serving CHEST membership and aligning closer with curriculum categories and other CHEST priorities.

The Networks Task Force was led by Co-Chairs, Aneesa Das, MD, FCCP, and David Zielinski, MD, FCCP, along with Council of Networks Chair, Angel Coz, MD, FCCP; Jack Buckley, MD, MPH,

FCCP; Christopher Carroll, MD, FCCP; De De Gardner, DrPH, RRT, FCCP; Sandhya Khurana, MD, FCCP; and David Schulman, MD, FCCP. They focused on learning what Networks aspects worked, what could be improved, and how to increase the Networks' overall influence and visibility.

The task force attentively listened to member comments and considered the insight and feedback from Network steering committee leaders. The group learned that Network priorities should include:

- Creating sustainable resources for Network members.
- Increasing digital presence.

• Generating additional leadership pathways and opportunities.

After 2 years of investigation and thoughtful strategic planning, the task force presented a plan to the Council of Networks for a new structure to achieve these objectives. The Governance Committee and College Board of Regents accepted the proposal in summer 2021.

Under the new structure, previously defined steering committees are now known as Sections. There are 22 Sections grouped under the leadership umbrella of 7 Networks. The Networks are composed of the Section chairs, vice-chairs and members-at-large. The Council of Networks still provides oversight. This layered approach is intended to help reduce silos and support improved collaboration between groups.

You might notice that many of the new Sections promote different areas of interest. These changes allow the groups to align closer to CHEST's curriculum areas. The Networks are better positioned to act as content experts in more CHEST initiatives. The new Sections each

focus on a specific curriculum area of pulmonary, critical care, and sleep medicine.

You will also notice that not all of the original individual Networks mapped over into the new structure. The Task Force determined that these special interests have broad appeal across all domains and would benefit from collective curriculum integration rather than being relegated to individual Sections. The decision to dissolve these individual steering committees was neither taken lightly, nor was it easy. The intent is that these interest areas



COURTESY CHEST

Continued on following page



Mitch Feldman speaks at the 2020 Irv Feldman Texas Hold 'Em Annual Tournament & Casino Night.

CONNECTED continued from previous page

Poker player and recent winner of one of the tournaments, Kim Coles started playing professionally during the pandemic and enjoys playing in an online environment.

"I had participated in charity poker tournaments before, but it wasn't until I joined Poker Power—a group focused on teaching women how to play poker—that I really came to the table ready to compete," says Coles. "Playing in an online setting is a lot more accessible for a lot of people, especially for women. A traditional poker tournament can be intimidating to a new player, but online has a way of evening

the playing field."

In an online setting, Feldman and Coles both note that buying in is a lot easier and lends itself well to fundraising.

"There is no fumbling around for your wallet or having to swipe your credit card," says Coles. "It's just the press of a button, and your credit card is already linked. It's all going to a good cause, so it makes sense to keep buying in to keep playing."

Looking into the future, while Feldman says that the virtual events have been successful, there's nothing like in-person.

"Through our virtual events, we were able to expand our network of players beyond the

Chicagoland area, and these individuals have expressed their interest in attending our live events," says Feldman. "With this extended network, I am very much looking forward to being able to get together in-person again for what I expect be one of our best tournaments to date."

The 8th Annual Irv Feldman Texas Hold 'Em Annual Tournament & Casino Night will be held in early April 2022 in the Chicago suburbs, and all are welcome to attend. Visit the CHEST Foundation's website to learn more about the tournament and upcoming events at chestfoundation.org. ■

Our CHEST 2021 Award Recipients

ANNUAL AWARDS

Master FCCP

Curtis N. Sessler, MD, Master FCCP

College Medalist Award

Margaret Pisani, MD, MPH, FCCP

Distinguished Service Award

Christopher Carroll, MD, FCCP

Master Clinician Educator

Doreen Addrizzo-Harris, MD, FCCP

Early Career Clinician Educator

Matthew C. Miles, MD, FCCP

Alfred Soffer Award for Editorial Excellence

Scott Manaker, MD, PhD, FCCP

Presidential Citation

COVID-19 Task Force

Ryan Maves, MD, FCCP

Christopher Carroll, MD, FCCP

Neha Dangayach, MD

Jeffrey Dichter, MD, FCCP

Alice Gallo De Moraes, MD

James Geiling, MD, MPH, FCCP

Holly Keyt, MD, FCCP

Stephanie M. Levine, MD, FCCP

Septimu Murgu, MD, FCCP

Marcos Restrepo, MD, PhD, FCCP

Steven Q. Simpson, MD, FCCP

Angel Coz Yataco, MD, FCCP

Staff: Katlyn Froslan,

Heather Watkins, Robb Rabito,

CHCP, Lilly Rodriguez,

Karla Velilla

HONOR LECTURE AND MEMORIAL AWARDS

Distinguished Scientist Honor Lecture in Cardiopulmonary Physiology

KENNETH I. BERGER, MD, FCCP

Probing the Small Airways in the Assessment of Dyspnea

The lecture is generously funded by the CHEST Foundation.

Presidential Honor Lecture

CURTIS N. SESSLER, MD, MASTER FCCP

Navigating the Road to Well-Being in the ICU

Margaret Pfrommer Endowed Memorial Lecture in Home-Based Mechanical Ventilation

DEBRA WEESE-MAYER, MD

Artificial Ventilation, a True

Life-Saver for Children with CCHS & ROHHAD

The Margaret Pfrommer Endowed Memorial Lecture in Home-Based Mechanical Ventilation is generously supported by International Ventilator Users Network of Post-Polio Health International and the CHEST Foundation.

Richard S. Irwin, MD, Master FCCP Honor Lecture

PETER J. MAZZONE, MD, MPH, FCCP

Shared Decision Making in the Evaluation and Management of Early Stage Lung Cancer

The lecture is generously funded by the CHEST Foundation.

Edward C. Rosenow III, MD, Master FCCP/Master Teacher Honor Lecture

DIANE E. STOVER, MD, FCCP

The Many Faces of Organizing Pneumonia—What's the O(O)P With That?

The lecture is generously funded by the CHEST Foundation.

Pasquale Ciaglia Memorial Lecture in Interventional Medicine

MICHAEL J. SIMOFF, MD, FCCP

Robotic Bronchoscopy: Platform to the Future?

The lecture is generously funded by the CHEST Foundation.

Roger C. Bone Memorial Lecture in Critical Care

OGNJEN GAJIC, MD, FCCP

Patient Comes First: Prioritizing Relevant From Irrelevant in Critical Care Medicine

The lecture is generously funded by the CHEST Foundation.

Thomas L. Petty, MD, Master FCCP Memorial Lecture

JEAN BOURBEAU, MD, FCCP

Pulmonary Rehabilitation and Self-Management in COPD: Understanding the Past to Build the Future

The lecture is generously funded by the CHEST Foundation.

CHEST FOUNDATION GRANT AWARDS

CHEST Foundation Research Grant in Lung Cancer

This grant is supported by the CHEST Foundation.

Daniel Ryan, MD, Royal College of Surgeons Ireland, Dublin, Ireland

Microbial Signatures Associated With Malignant Pleural Effusions in Lung Cancer

CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease

This grant is jointly supported by the CHEST Foundation and RHA.

Miguel Divo, MD, Brigham and Women's Hospital, Boston, MA

Biomarker Profiles in Smokers Who Are at Risk of Developing Chronic Obstructive Pulmonary Disease (COPD)

CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease

This grant is supported by AstraZeneca LP.

Stephen Milne, MBBS, Woolcock Institute of Medical Research, Vancouver, BC, Canada

The Oral Metagenome in COPD: Towards a Biomarker of Exacerbation Risk

CHEST Foundation Research Grant in Critical Care

This grant is supported by the CHEST Foundation.

JACQUELINE STOCKING, PhD, University of California, Davis, Davis, CA
University of California Critical Care Research Collaborative: Predictive Model and Risk Calculator for Early and Late Postoperative Respiratory Failure

CHEST Foundation and the Alpha-1 Foundation Research Grant in Alpha-1 Antitrypsin Deficiency
This grant is jointly supported by the CHEST Foundation and the Alpha-1 Foundation.

JOHN CHARLES ROTONDO, PhD, University of Ferrara, Ferrara, Italy
Alpha-1 Antitrypsin Protein as a Possible Marker of Disease Progression in COVID-19 Patients

CHEST Foundation Research Grant in Nontuberculous Mycobacteria Diseases
This grant is supported by Insmad Incorporated.

EDWARD CHAN, MD, Rocky Mountain Regional Veterans Affairs Medical Center, Denver, CO
Visualization and Quantitation of Azithromycin, Clofazimine, and Amikacin Distribution in Surgically Removed Lung Tissues From Patients With Nontuberculous Mycobacterial Lung Disease

CHEST Foundation Research Grant in Cystic Fibrosis
This grant is supported by Vertex Pharmaceuticals Incorporated.

SHAHID SHEIKH, MD, FCCP, Nationwide Children's Hospital, Columbus, OH
Impact of CFTR Modulator Therapy Elexacaftor-Tezacaftor-Ivacaftor on CF-Related Chronic Sinus Disease

John R. Addrizzo, MD, FCCP Research Grant in Sarcoidosis
This grant is in honor of John R. Addrizzo, MD, FCCP and is jointly sup-

CHEST NETWORKS *continued from previous page*

will have increased access to resources and support under the expanded structure.

We are optimistic this new structure will enhance your Network experience. As with any meaningful change, we may face some growing pains along the way. Your Network leadership is open to feedback and making adjustments to better serve the CHEST membership.

Here are your ways to stay (or get) involved with the Networks and be informed.

• Subscribe to receive the latest information on

topics most important to you by joining a Network. Network membership gives you access to Network News, a bi-yearly communication from your Network chair with relevant education course offerings, key events in the CHEST community, and up-to-date information on happenings in your Network.

- Join multiple Networks, or change your affiliation any time, by logging in to your CHEST Account, and indicate your preferences on the Networks page.
- Apply for a position when the call for nomina-

tions opens. Keep an eye out soon for an announcement

- Join a Network call. Contact the Networks staff liaison for access to the call information. Call information will be available soon on the individual Network webpages.

In the meantime, please take a few minutes to become acquainted with our new structure. Visit the new Network webpages at chestnet.org/networks.

We hope you are as excited as we are with what's in store for CHEST members. ■

ported by the Addrizzo family and the CHEST Foundation.

MANEESH BHARGAVA, MD, PhD, FCCP, Minneapolis VA Health Care System, Minneapolis, MN
Inflammatory Protein Panel for Sarcoidosis Diagnosis and Prognosis

CHEST Foundation Research Grant in Severe Asthma
This grant is supported by the CHEST Foundation.

FELIX REYES, MD, Montefiore Medical Center, Bronx, NY
Design and Implementation of an Asthma Action Plan Generator: A Pilot Study Assessing User Satisfaction and Clinical Impact

CHEST Foundation Research Grant in Pulmonary Fibrosis
These grants are supported by an independent grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc.

MARCO MURA, MD, PhD, Western University, London, Ontario, Canada
Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis

JANELLE PUGASHETTI, MD, University of California, Davis, Davis, CA
Determining Biomarkers of Immunosuppressant Responsiveness in Patients With CTD-ILD

CHEST Foundation Research Grant in Pulmonary Hypertension
These grants are supported by the CHEST Foundation.

MICHAEL LEE, MD, University of California San Francisco, San Francisco, CA
Transpulmonary Metabolomic Gradients During Exercise in Systemic Sclerosis-Associated Pulmonary Hypertension

NAVNEET SINGH, MD, Warren Alpert School of Medicine at Brown University, Providence, RI
Mitochondrial Dysfunction and Oxidative Stress in Pulmonary Hypertension

CHEST Foundation Research Grant in Sleep Medicine
These grants are funded by Jazz Pharmaceuticals, Inc.

SHAHID KARIM, MBChB, Mayo Clinic, Rochester, MN
Effects of OSA on Atrial and Ventricular Arrhythmia in HCM:

An Incidence Study

THOMAS TOLBERT, MD, Mount Sinai Hospital, New York, NY
Performance Characteristics of Obstructive Sleep Apnea Physiologic Traits Measured by Phenotyping Using Polysomnography

CHEST Foundation and American Academy of Sleep Medicine Foundation Research Grant in Sleep Medicine
This grant is jointly supported by the CHEST Foundation and AASM Foundation.

MARTA KAMINSKA, MD, McGill University Health Centre, Montreal, QC, Canada
Long-term Noninvasive Ventilation in COPD: Impact on Health Care Utilization

CHEST Foundation and APC-CMPD Research Grant in Medical Education
This grant is jointly supported by the CHEST Foundation and APCCMPD.

MARK ADELMAN, MD, NYU School of Medicine, New York, NY
Virtual Reality Simulation Training for the Management of Tracheostomy Emergencies

CHEST Foundation Research Grant in COVID-19
These grants are supported by the CHEST Foundation.

MARLENE CANO, MD, PhD, Washington University, St. Louis, MO
Circulating Mitochondrial DNA Is a Potential Biomarker for Severe Illness in COVID-19

BRANDON WALSH, MD, New York University, New York, NY
How Would Existing Ventilator Allocation Guidelines Perform During the COVID-19 Pandemic: A Retrospective Observational Simulated Cohort Study

CHEST Foundation and ATS Research Grant in COVID-19 and Diversity
These grants are jointly supported by the CHEST Foundation and ATS.

NAVITHA RAMESH, MD, FCCP, UPMC Harrisburg, Harrisburg, PA
Improving Lung Health in the Nepali-Bhutanese Refugee Community in Harrisburg, PA

INDERJIT SINGH, MBChB, Yale University, New Haven, CT
Dynamic Invasive Hemodynamic,

Echocardiographic, and Plasma Biomarker Phenotyping in Post-COVID-19 Long Hauler Syndrome

CHEST Foundation Community Service Grants Honoring D. Robert McCaffree, MD, Master FCCP

VALERIE ANDREWS, BS, The JUDAHH Project, Sacramento, CA
Asthma Mitigation Project

CHANDA HOLSEY, DRPH, National Medical Association, Silver Spring, MD
Providing Lung Health Education to At Risk Communities

ARZU ARI, PHD, FCCP, Texas State University, San Marcos, TX
Training Future Respiratory Care Practitioners in Turkey: A Path to Successful Disease Management in Pulmonary Medicine

PANAGIS GALIATSATOS, MD, MPH, John Hopkins University, Baltimore, MD
The Lung Health Ambassador Program: A Health Equity Initiative for Cystic Fibrosis

PATRICIA GEORGE, MD, National Jewish Health, Denver, CO

Development of Breathe Strong PH: An Informational Website About Pulmonary Hypertension and Related Diseases

NISHANT GUPTA, MD, MS, University of Cincinnati, Cincinnati, OH
Global Dissemination of the Lymphoangiomyomatosis (LAM) Clinical Practice Guidelines

SYED NAQVI, MD, MBBS, Hoag Hospital Newport Beach, Newport Beach, CA
Asthma Management in Rural Pakistan
These grants are supported by the CHEST Foundation.

Alfred Soffer Research Award Winners
Mathieu Saint-Pierre, MD: *Methacholine Challenge Testing: A Clinical Prediction Model Utilizing Demographic Data And Spirometry Results*

Tie:
MILIND K BHAGAT, MD: *High Flow Nasal Cannula Fio2 Cutoffs Identified Early In The Hospital Course Are Associated With Increased Mortality Risk In Hospitalized Patients With COVID-19*

Continued on following page

SAVE THE DATE

CHEST 2022
Nashville, Tennessee
October 16-19

Gather at CHEST 2022 to connect with the entire chest medicine team. Watch for these opportunities to share your knowledge and skills, and get involved and be part of this can't-miss event!

- Nominate an honor lecturer or award winner.
- Submit an abstract or case report.
- Enter to compete in CHEST Challenge.

Watch for announcements at chestnet.org.

 CHEST®

2022 COURSES

CHEST Global Headquarters | Glenview, IL



MAR 11-12	Mechanical Ventilation: Critical Care Management
MAR 17-19	Comprehensive Bronchoscopy With Endobronchial Ultrasound
MAR 24-25	Ultrasonography: Essentials in Critical Care
APR 22-23	Advanced Clinical Training in Pulmonary Function Testing
APR 28-30	Critical Skills for Critical Care: A State-of-the-Art Update and Procedures for ICU Providers
MAY 12-13	Advanced Critical Care Echocardiography: Image Acquisition and Interpretation
MAY 19-20	Therapeutic Bronchoscopy for Airway Obstruction With Cadavers
MAY 21	Bronchoscopy and Chest Tubes in the ICU With Cadavers
JUN 2-4	Difficult Airway Management
JUN 9-10	Ultrasonography: Essentials in Critical Care
JUL 22-23	Mechanical Ventilation: Critical Care Management
AUG 5-6	Cardiopulmonary Exercise Testing
AUG 26-27	NEW! Advanced Diagnostic Bronchoscopy for Peripheral Nodules
SEP 8-10	Difficult Airway Management
SEP 15-16	Ultrasonography: Essentials in Critical Care
SEP 22-24	Comprehensive Bronchoscopy With Endobronchial Ultrasound
NOV 10-11	Critical Care Ultrasound: Integration Into Clinical Practice
NOV 18	Comprehensive Pleural Procedures With Cadavers
NOV 19	Advanced Airway Management With Cadavers
DEC 1-2	Ultrasonography: Essentials in Critical Care
DEC 9-10	Extracorporeal Support for Respiratory and Cardiac Failure in Adults
DEC 6, 13, 15	Virtual Advanced Critical Care Echocardiography Board Review Course

LEARN MORE AND REGISTER
chestnet.org/simulation

NEWS FROM CHEST

AWARDS *continued from previous page*

AMBER J MESERVEY, MD: *Outcomes Of Patients Across The Spectrum Of Pulmonary Hypertension Groups Prescribed Inhaled Treprostinil*

Young Investigator Award Winners

WILLIAM B. FELDMAN, MD: *COPD Exacerbations And Pneumonia Hospitalizations In New Users Of Combination Maintenance Inhalers: A Comparative Effectiveness And Safety Study*

CHRISTOPHER STREILER, MD: *Community Pulmonologist Access To Multidisciplinary Discussion At An Academic Referral Center Leads To Changes In Management Of Interstitial Lung Disease*

Top 5 Abstract Posters

Winner: RILEY KERMANIAN: *Management Of Coronary Artery Calcification In Patients Enrolled In A Low-Dose Computerized Tomography Lung Cancer Screening Program*

Winner: ROHIT REDDY: *Outcomes Of Extracorporeal Membrane Oxygenation In ARDS Due To Covid-19: Comparison Of The First And The Second Wave*

Winner: TAYLOR A. INTIHAR, BA: *Light Patterns Of The Medical ICU: Are We Disrupting Circadian Rhythms?*

Runner up: JASON WONG, MD: *Completion Of Pulmonary Rehabilitation Is Associated With Improvement In Depression Scores And Other Quality Of Life Measures In Patients With Interstitial Lung Disease*

Runner up: HARSHIL SHAH, MD: *Impact Of Sepsis On Outcomes Of Hospitalizations Due To COPD*

Case Report Session Winners

Remarkable Pulmonary Cases:
MENA BOTROS, MD: *Clinical Outcomes In Lung Transplant Recipients With SARS-COV2*

Bacterial Infections: **BENJAMIN CARMEL, DO:** *Cotton Swab Today, Brain Abscess Tomorrow*

Challenging Critical Care Cases:
RAJANINDER SHARMA, MD: *Pulmonary Tumor Thrombotic Microangiopathy: The Rare And Fatal Association Of Adenocarcinoma And Right Ventricular Failure*

Diffuse Lung Diseases: **RIZWANA RR RANA, MBBS:** *A Rare Cause Of Pulmonary Nodules*

Viruses, Fungi, and Parasites In-

fections: **MICHELLE FORSON, MD:** *Strongyloidiasis-Related Eosinophilic Pleural Effusion: An Unexpected Differential For Post-Cardiac Injury Syndrome*

Critical Care Cases: Act Quickly:
CHRISTINA JEE AH RHEE, MD: *Airway Implications Of Cricoarytenoid Arthritis: A Report And Review Of The Literature*

Airway Issues: **BENADIN VARAJIC, MD:** *An Unusual And Life-Threatening Complication Of Endotracheal Intubation*

Miscellaneous Cases 1: **SHREY SHAH, MD:** *A Case Of Pulmonary Arterial Hypertension From Vitamin C Deficiency*

Miscellaneous Cases 2: **GLENN W. POTTMEYER, DO, MPH:** *Biliary Stent Migration: A Rare Cause Of Right-Sided Pulmonary Abscess*

Case Report Poster Winners

Advanced Cancer Case Report Posters: **SANGITA GOEL, MD:** *Let's Meet in the Middle: Simultaneous Endoscopic and Bronchoscopic Suture Repair to Close a Left Main-Stem Malignant Broncho-Esophageal Fistula*

Cardiovascular Case Report Posters: **Marianna Weaver, DO:** *Swan-Ganz And Intra-Pericardial Pressure Guided Pericardiocentesis in Scleroderma-Associated PAH*

Remarkable Cases Posters 1: **Katie Capp, MD:** *Humidifier-Associated Hypersensitivity Pneumonitis*

Remarkable Cases Posters 2: **Sahar Samani, MD:** *Artifactual Hypoxemia in Patients With Hydroxyurea-Induced Blue Lunula Fingernails*

CHEST 2021 CHEST CHALLENGE

1st Place

The Ohio State University
SARAH COHEN, MD
GREGORY EISINGER, MD
KYLE STINEHART, MD
Program Director: Jennifer McCallister, MD, FCCP

2nd Place

SUNY Buffalo
ARJUN SARADNA, MBBS
RAJESH KUNADHARAJU, MD
AHMED MUNIR, MBBS
Program Director: Jeffrey Mador, MD

3rd Place

Interfaith Medical Center
TAHMINA JAHIR, MD
RUBY RISAL, MD
BINAV SHRESTHA, MBBS
Program Director: Marie Frances Schmidt, MD, FCCP ■

SLEEP STRATEGIES

An update on the recall of PAP and HMV devices

BY SREELATHA NAIK, MD

Case 1: A 53-year-old man was newly diagnosed with atrial fibrillation (AFIB). He was started on a regimen of metoprolol tartrate and apixaban. He is planned for cardioversion by his cardiologist and referred to sleep medicine for evaluation and management of obstructive sleep apnea (OSA). A polysomnogram demonstrated an apnea hypopnea index of 32 events per hour, and continuous positive airway pressure therapy (CPAP) of 9 cm H₂O was determined to be optimal. A new CPAP device was ordered. The patient was scheduled for cardioversion the following month but is still awaiting CPAP therapy. Patients with untreated sleep apnea have higher rates of recurrent AFIB after cardioversion in comparison to treated OSA (Kanagala R, et al. *Circulation* 2003;107:2589-2594).

Case 2: A 68-year-old man with severe COPD, chronic hypoxic respiratory failure on 2 L of oxygen at rest, pulmonary hypertension, and comorbid severe OSA. He is adherent to CPAP therapy but recently learned that his device was part of a recall. Given his chronic nasal congestion and cough, he is concerned that these symptoms may be related to his recalled device and decided to discontinue treatment until the device is replaced. His device was set up 3 years ago, therefore, he is unable to receive a new one through his insurer. He registered his device with the recall website and is awaiting for repair or a replacement and had heard that it may be a year from now.

Case 3: A 65-year-old woman had progressive respiratory failure due to amyotrophic lateral sclerosis. She uses the home mechanical ventilator (Trilogy 100) all night and intermittently during the daytime with improved sleep quality, fatigue, and shortness of breath. She received the recall notice and would like to know if she has alternative options, as she is dependent on the ventilator and doesn't think that she can stop therapy safely.

While hypothetical, the cases above illustrate the challenges with patient care that medical providers are facing nationally. On June 14, 2021,

Philips Respironics announced a voluntary recall of many of their positive airway pressure (PAP) therapy, noninvasive ventilation (NIV), and home mechanical ventilation (HMV) devices. This recall is related to a polyester-based polyurethane (PE-PUR) foam used for sound abatement from these devices. Philips reports on their website that 1) PE-PUR foam may degrade into particles which may enter the device's air delivery pathway and be ingested or inhaled by the user, and 2) the PE-PUR foam may off-gas certain toxic chemicals.



Dr. Naik

The foam degradation may be exacerbated by use of unapproved cleaning methods, such as ozone and off-gassing may occur during initial operation and may possibly continue throughout the device's useful life" [www.philips.com/SRC-update]. The FDA warns that "this particular foam may break down and can result in serious injury, which can be life-threatening, cause permanent impairment, and require medical intervention to prevent permanent injury to users." Potential symptoms include rhinitis and sinusitis, upper airway irritation, cough, chest pressure, headache, or dizziness.

The guidance from Philips is as follows:

1. Patients using a recalled life-sustaining home mechanical ventilator device should continue therapy until discussion with the health care provider.
2. Patients using a recalled CPAP or BiPAP device should discuss with the health care provider a suitable treatment plan.

It is estimated that between 3 and 4 million patients are impacted by this recall. Many practices across the country have been immensely challenged with finding the means to reach out to large panels of patients, while still keeping individual risk factors in mind. Commonly prescribed devices that are impacted include the Dream Station and System One devices that provide PAP therapy for OSA, Auto Servoventilation for central sleep apnea, BiPAP therapy for treatment of hypoventilation, as well as Trilogy 100 and Trilogy 200 home mechanical ventilators for chronic respiratory failure syndromes. A complete list of devices impacted can be found at www.philips.com/SRC-up-

date. In addition to ambulatory uses in the home setting, many sleep centers utilize Philips Respironics OmniLab Advanced Plus platforms for in-laboratory titration polysomnograms. Facility-based titration studies are, therefore, heavily impacted by this recall, as well.

Patients may register for a replacement device or repair with Philips via Philips hotline or through its website; however, given the large number of patients, the replacement process plan can be prolonged and estimated up to 12 months or longer. Philips has initiated a repair and replace program whereby the PE-PUR foam would be replaced by a silicone-based foam. The FDA has initially approved this proposal. Most recently, the FDA obtained additional information regarding the silicone-based foam used in a device outside of United States, which failed a safety test due to release of certain

It is estimated that between 3 and 4 million patients are impacted by this recall.

volatile organic compounds. While similar testing provided by Philips Respironics on devices in United States provided acceptable results, the FDA requested that Philips Respironics perform additional testing with the silicone-based foam. The FDA does not recommend discontinuation of the devices in the repair and replace program at this time.

While patients may attempt to purchase devices unaffected by the recall at an out of pocket expense, there is a limited supply of PAP devices nationally with a back-log of 3 months or longer. This has been a challenge particularly for patients waiting to initiate treatment for newly diagnosed with sleep-disordered breathing. Availability of devices for newly-diagnosed patients, as well as patients' hesitation/unwillingness to adhere to therapy due to fear of potential risks, will impact medical providers ability to care for patients, and likely will have significant consequences to overall patient health outcomes.

It is important for the provider to have a discussion with the patient and review the following in order to best determine a course of action:

- Severity/stage of disease

- Usage/adherence
- Clinical benefits of ongoing treatment
- Alternative therapies

While it would be optimal to replace recalled devices, providers caring for patients face challenging limitations. The following are options to consider: 1) Determine if device is past 5-year mark and if patient is eligible for new device (PAP devices only); 2) For patients with chronic respiratory failure, review disease progression, adherence and device usage (eg, if usage is > 12 hours per 24-hour period, consider switching the PAP device to a home mechanical ventilator); 3) For patients on full time invasive mechanical ventilatory support, consider switching to a non-Philips home mechanical ventilator.


A patient who is using a respiratory assist device or life-sustaining home mechanical ventilator for chronic respiratory failure may not be able to stop treatment. Conversely, it may be reasonable for a patient with mild OSA who has been struggling with adherence to temporarily stop treatment. For OSA treatment, it is advisable to consider alternative options including mandibular advancement devices, sleep surgery, or new noninvasive therapies. There are medical, logistical, and ethical challenges as we navigate through this recall, and it is important to engage the patient in an informed discussion regarding risks and benefits of therapy when determining the best course of action (Owens RL, et al. *Am J Respir Crit Care Med* 2021; 204(8):887-890).

Dr. Naik is Program Director, Sleep Medicine Fellowship; Director, Sleep Medicine; and Clinical Assistant Professor, Geisinger Commonwealth School of Medicine, Wilkes-Barre, PA.

NOTE: CHEST is providing resources for its members and others with regular updates on the Philips recall. Check at chestnet.org. ■

INDEX OF ADVERTISERS

Biodesix Nodify	24
Boehringer Ingelheim Pharmaceuticals, Inc. Ofev	6-12
EchnoNous, Inc. Kosmos	17



Reclassify
risk.
Reduce
uncertainty.

nodifylung[®]
NODULE RISK ASSESSMENT

nodifycdt[®]
PROTEOMIC TEST

nodifyxl2[®]
PROTEOMIC TEST

Designed to help providers quickly and more confidently decipher the risk of malignancy of a lung nodule from a simple blood draw.

Visit www.nodify.com for more information.

 **biodesix**[®]

